

NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003

=> file regt

'REGT' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'HOME'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4

DICTIONARY FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> s pantothenic acid

AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-HIV activities in existing drugs which are
 suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan
 SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English
 CC 10-5 (Microbial Biochemistry)
 AB Anti-HIV activities of 58 com. drugs available for long-term
 administration without significant side effects were investigated.
 Lorazepam, Ca hopantenate, prochlorperazine maleate, amantadine HCl,
 perphenazine (I) and nitrazepam (II) were found to exhibit anti-
 HIV activity in MT-4 cells. But only I and II did so without
 cytotoxicity. In peripheral blood mononuclear cells, I exhibited only
 weak anti-HIV activity, while II showed none.
 ST AIDS HIV virus drug screening perphenazine
 IT Virucides and Virustats
 (for AIDS treatment, screening of)
 IT Immunodeficiency
 (acquired immune deficiency syndrome, perphenazine and other drugs for
 treatment of)
 IT Virus, animal
 (human immunodeficiency 1, perphenazine and other drugs effect on)
 IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5,
 Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam
 17097-76-6, Calcium hopantenate
 RL: BIOL (Biological study)
 (anti-HIV virus activity of, cytotoxicity in relation to)

=>

RN 17097-76-6 REGISTRY
 CN Butanoic acid, 4-[[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]amino]-, calcium salt (2:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Butanoic acid, 4-[(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)amino]-, calcium salt (2:1), (R)-
 CN Butyric acid, 4-(2,4-dihydroxy-3,3-dimethylbutyramido)-, calcium salt (2:1), D-(+)- (8CI)
 OTHER NAMES:
 CN Calcium D-(+)-homopantothenate
 CN Calcium D-homopantothenate
 CN Calcium homopantothenate
 CN Calcium hopantenate
 CN D-(+)-Homopantothenic acid calcium salt
 CN Hopantenate calcium
 CN Pantogam
 CN Vivant
 FS STEREOSEARCH
 MF C10 H19 N O5 . 1/2 Ca
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IPA, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN
 (*File contains numerically searchable property data)
 CRN (18679-90-8)

Absolute stereochemistry.



● 1/2 Ca

115 REFERENCES IN FILE CA (1957 TO DATE)
 115 REFERENCES IN FILE CAPLUS (1957 TO DATE)

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA
NEWS	41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	43	Jun 06	PASCAL enhanced with additional data


104 PANTOTHENIC
 5972582 ACID
 L1 101 PANTOTHENIC ACID
 (PANTOTHENIC(W)ACID)

 => s vitamin b5
 1477 VITAMIN
 1478 B5
 L2 2 VITAMIN B5
 (VITAMIN(W)B5)

 => d 12 1-2

 L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
 RN 137-08-6 REGISTRY
 CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-, calcium
 salt (2:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, calcium salt
 (2:1), (R)-
 CN Calcium, bis(pantothenato)- (7CI)
 CN Pantothenic acid, calcium salt (2:1), D- (8CI)
 OTHER NAMES:
 CN (+)-Pantothenic acid calcium salt
 CN Calcium D-(+)-N-(.alpha.,.gamma.-dihydroxy-.beta.,.beta.-dimethylbutyryl)-
 .beta.-alaninate
 CN Calcium D-(+)-pantothenate
 CN Calcium D-pantothenate
 CN Calcium pantothenate
 CN Calpan
 CN Calpanate
 CN Dextro calcium pantothenate
 CN N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine calcium
 CN Pancal
 CN Panthoject
 CN Pantholin
 CN Pantothenate calcium
 CN Pantothenic acid calcium salt
 CN Pantothenic acid hemicalcium salt
 CN **Vitamin B5 calcium salt**
 FS STEREOSEARCH
 DR 7693-16-5, 533-61-9, 138932-10-2
 MF C9 H17 N O5 . 1/2 Ca
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
 MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER,
 TULSA, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (79-83-4)

Absolute stereochemistry. Rotation (+).




● 1/2 Ca

1164 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1165 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
 RN 79-83-4 REGISTRY
 CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-
 CN Pantothenic acid, D- (8CI)
 OTHER NAMES:
 CN (+)-Pantothenic acid
 CN (D)-(+)-Pantothenic acid
 CN Chick antidermatitis factor
 CN D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine
 CN D-Pantothenic acid
 CN Pantothenic acid
 CN Vitamin B3
 CN **Vitamin B5**
 FS STEREOSEARCH
 DR 3563-85-7
 MF C9 H17 N O5
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4401 REFERENCES IN FILE CA (1957 TO DATE)

125 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4405 REFERENCES IN FILE CAPLUS (1957 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s vitamin b3
1477 VITAMIN
2455 B3
L3 2 VITAMIN B3
(VITAMIN(W) B3)


=> d l2 not l3
L3 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l2 not l3
L4 1 L2 NOT L3

=> d l4

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 137-08-6 REGISTRY
CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-, calcium
salt (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, calcium salt
(2:1), (R)-
CN Calcium, bis(pantothenato)- (7CI)
CN Pantothenic acid, calcium salt (2:1), D- (8CI)
OTHER NAMES:
CN (+)-Pantothenic acid calcium salt
CN Calcium D-(+)-N-(.alpha.,.gamma.-dihydroxy-.beta.,.beta.-dimethylbutyryl)-
.beta.-alaninate
CN Calcium D-(+)-pantothenate
CN Calcium D-pantothenate
CN Calcium pantothenate
CN Calpan
CN Calpanate
CN Dextro calcium pantothenate
CN N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine calcium
CN Pancal
CN Panthoject
CN Pantholin
CN Pantothenate calcium
CN Pantothenic acid calcium salt
CN Pantothenic acid hemicalcium salt
CN **Vitamin B5 calcium salt**
FS STEREOSEARCH
DR 7693-16-5, 533-61-9, 138932-10-2
MF C9 H17 N O5 . 1/2 Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER,
TULSA, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (79-83-4)

Absolute stereochemistry. Rotation (+).



● 1/2 Ca

1164 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1165 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

31.16

31.37

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2003 VOL 139 ISS 2

FILE LAST UPDATED: 6 Jul 2003 (20030706/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
 L2 2 S VITAMIN B5
 L3 2 S VITAMIN B3
 L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

=> s l1

L5 5882 L1

=> e retroviral

E1	15	RETROVIAL/BI
E2	34	RETROVIR/BI
E3	13558	--> RETROVIRAL/BI
E4	1	RETROVIRALES/BI
E5	683	RETROVIRALLY/BI
E6	9	RETROVIRALS/BI
E7	1	RETROVIRALVECTOR/BI
E8	5	RETROVIREMIA/BI
E9	1	RETROVIREMIC/BI
E10	1	RETROVIRES/BI
E11	1	RETROVIRIAL/BI
E12	1	RETROVIRICIDAL/BI

=> s e1-e6

	15	RETROVIAL/BI
	34	RETROVIR/BI
	13558	RETROVIRAL/BI
	1	RETROVIRALES/BI
	683	RETROVIRALLY/BI
	9	RETROVIRALS/BI
L6	13948	(RETROVIAL/BI OR RETROVIR/BI OR RETROVIRAL/BI OR RETROVIRALES/BI OR RETROVIRALLY/BI OR RETROVIRALS/BI)

=> s hiv

L7 50063 HIV

=> s l7 or l6

L8 61642 L7 OR L6

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1	101	S PANTOTHENIC ACID
L2	2	S VITAMIN B5
L3	2	S VITAMIN B3
L4	1	S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5	5882	S L1
		E RETROVIRAL
L6	13948	S E1-E6
L7	50063	S HIV
L8	61642	S L7 OR L6

=> s l5 and l8

L9 8 L5 AND L8

=> d l9 1-8

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2003:76964 CAPLUS

DN 138:133150

TI Human pantothenate kinase and cDNA and methods for diagnosing
predisposition to and treating of neurodegenerative disorders

IN Hayflick, Susan J.; Gitschier, Jane; Zhou, Bing; Westaway, Shawn;
Levinson, Barbara; Johnson, Monique

PA Oregon Health and Science University, USA; The Regents of the University
of California

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003008626	A2	20030130	WO 2002-US22952	20020719
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-307081P	P	20010720		
	US 2001-308055P	P	20010725		

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2002:745859 CAPLUS

DN 137:277454

TI A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis

AU Sambandamurthy, Vasan K.; Wang, Xiaojuan; Chen, Bing; Russell, Robert G.; Derrick, Steven; Collins, Frank M.; Morris, Sheldon L.; Jacobs, William R.

CS Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY, USA

SO Nature Medicine (New York, NY, United States) (2002), 8(10), 1171-1174
CODEN: NAMEFI; ISSN: 1078-8956

PB Nature Publishing Group

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2002:293978 CAPLUS

DN 136:337341

TI Materials and methods to modulate ligand binding/enzymic activity of .alpha./.beta. proteins containing an allosteric regulatory site

IN Stauton, Donald E.

PA Icos Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002031511	A2	20020418	WO 2001-US32047	20011012
	WO 2002031511	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002013196 A5 20020422 AU 2002-13196 20011012
 US 2003088061 A1 20030508 US 2001-976935 20011012
 PRAI US 2000-239750P P 20001012
 WO 2001-US32047 W 20011012

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2001:570199 CAPLUS

DN 136:35788

TI A novel pantothenate kinase gene (PANK2) is defective in
 Hallervorden-Spatz syndrome

AU Zhou, Bing; Westaway, Hawn K.; Levinson, Barbara; Johnson, Monique A.;
 Gitschier, Jane; Hayflick, Susan J.

CS Howard Hughes Medical Institute and Departments of Medicine and
 Pediatrics, University of California, Parnassus, CA, 94143, USA

SO Nature Genetics (2001), 28(4), 345-349

CODEN: NGENEC; ISSN: 1061-4036

PB Nature America Inc.

DT Journal

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2001:6065 CAPLUS

DN 134:37051

TI Method for immune-system strengthening and development of a lipid
 transporter for anti-HIV and antibacterial gene therapy

IN Worm, Richard; Correa, Michel; Mavoungou, Donatien

PA Can.

SO Fr. Demande, 16 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2792201	A1	20001020	FR 1999-4706	19990415
	FR 2792201	B1	20011102		
PRAI	FR 1999-4706		19990415		

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and
 other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,				
	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
	UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

US 6350784	B1	20020226	US 1997-824041	19970326
AU 9867718	A1	19981020	AU 1998-67718	19980324
AU 727339	B2	20001207		
BR 9807892	A	20000222	BR 1998-7892	19980324
EP 980203	A1	20000223	EP 1998-913086	19980324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

EE 9900436	A	20000417	EE 1999-436	19980324
NZ 500002	A	20010928	NZ 1998-500002	19980324
JP 2001527541	T2	20011225	JP 1998-545926	19980324
NO 9904639	A	19991124	NO 1999-4639	19990924
MX 9908750	A	20000331	MX 1999-8750	19990924
BG 63612	B1	20020731	BG 1999-103786	19991007

PRAI US 1997-824041 A 19970326
US 1996-600217 A2 19960212
US 1996-646988 A2 19960508
WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (HIV)
infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1990:232458 CAPLUS
DN 112:232458
TI Screening of anti-HIV activities in existing drugs which are
suitable for long-term oral administration
AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
CS Sch. Med., Tottori Univ., Yonago, 683, Japan
SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
CODEN: NKRZAZ; ISSN: 0009-3165
DT Journal
LA English

=> d 19 6 7 8 all

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1998:661494 CAPLUS
DN 129:298375
TI Antimicrobial prevention and treatment of human immunodeficiency virus and
other infectious diseases
IN Squires, Meryl
PA USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English

IC ICM A01N033-12
ICS A61K031-14
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6350784	B1	20020226	US 1997-824041	19970326
	AU 9867718	A1	19981020	AU 1998-67718	19980324
	AU 727339	B2	20001207		
	BR 9807892	A	20000222	BR 1998-7892	19980324
	EP 980203	A1	20000223	EP 1998-913086	19980324
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	EE 9900436	A	20000417	EE 1999-436	19980324
	NZ 500002	A	20010928	NZ 1998-500002	19980324
	JP 2001527541	T2	20011225	JP 1998-545926	19980324
	NO 9904639	A	19991124	NO 1999-4639	19990924
	MX 9908750	A	20000331	MX 1999-8750	19990924
	BG 63612	B1	20020731	BG 1999-103786	19991007
PRAI	US 1997-824041	A	19970326		
	US 1996-600217	A2	19960212		
	US 1996-646988	A2	19960508		
	WO 1998-US5792	W	19980324		
AB	An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.				
ST	phytochem nutrient antimicrobial HIV ; Echinacea Commiphora phytochem surfactant antimicrobial HIV ; folic acid phytochem antimicrobial HIV				
IT	Labia Lip Lymph node Lymphatic system T cell (lymphocyte) (administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Quaternary ammonium compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyltrimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Quaternary ammonium compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyltrimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Surfactants (amphoteric; antimicrobial prevention and treatment of human				

immunodeficiency virus and other infectious diseases)

IT Bacilli
 (anaerobic; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Allium
 Anise
 Arctostaphylos
 Artemisia
 Baptisia
 Calendula
 Capsicum
 Carum
 Compositae (Asteraceae)
 Coriandrum
 Echinacea angustifolia
 Echinacea atribactilus
 Echinacea pallida
 Echinacea purpurea
 Echinacea vegetalis
 Eucalyptus
 Eugenia mytacea
 Gentian (Gentiana)
 Inula
 Juniper (Juniperus)
 Labiatae (Lamiaceae)
 Meliosma
 Mentha
 Mentha aquatica hypeuria
 Myroxylon
 Origanum
 Parthenium integrifolium
 Plantago
 Rosemary
 Ruta
 Sage (Salvia)
 (antimicrobial isolates of; antimicrobial prevention and treatment of
 human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
 Antibacterial agents
 Antimicrobial agents
 Antiviral agents
 Arbovirus
 Arenavirus
 Bird (Aves)
 Cat (Felis catus)
 Cattle
 Commiphora erythraea
 Commiphora molmol
 Commiphora myrrha
 Coronavirus
 Cytomegalovirus
 Dog (Canis familiaris)
 Drug delivery systems
 Gums and Mucilages
 Horse (Equus caballus)
 Human herpesvirus 1
 Human herpesvirus 2
 Human herpesvirus 3
 Human herpesvirus 4
 Human immunodeficiency virus
 Human parainfluenza virus
 Influenza virus

Livestock
 Mycobacterium
 Nutrients
 Papillomavirus
 Picornaviridae
 Rodent
 Sexually transmitted diseases
 Sheep
 Staphylococcus
 Streptococcus
 Surfactants
 Swine
 (antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT Amides, biological studies
 Anthocyanins
 Enzymes, biological studies
 Natural products, pharmaceutical
 Polyacetylenes, biological studies
 Polysaccharides, biological studies
 Proteins, general, biological studies
 Sesquiterpenes
 Tannins
 Vitamins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT Encephalitis
 Meningitis
 (bacterial and viral; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Detergents
 Surfactants
 (cationic; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Inflammation
 (cellulitis; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (derivs.; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Vitamins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (fat-sol.; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (injections; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Mouth
 (mucosa, administration to; antimicrobial prevention and treatment of
 human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (nasal; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Surfactants

(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid 536-60-7, Cumic alcohol 548-75-4, Quercetagenin-7-glucoside 563-83-7

593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone
 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6,
 Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E
 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide
 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies
 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic
 acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin
 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7,
 .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4,
 Magnesium, biological studies 7439-96-5, Manganese, biological studies
 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological
 studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium,
 biological studies 7723-14-0, Phosphorus, biological studies
 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronooarabinoxylan
 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
 biological studies 16887-00-6, Chloride, biological studies
 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
 Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0
 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
 69350-61-4, Epishyobunol 74282-22-7 75081-19-5, Pentadecadiene
 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
 125199-93-1 148879-89-4, Commiphoric acid 149531-55-5,
 .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
 .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7,
 Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium
 chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
 Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium
 chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(complex; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(surfactant; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bryant; US 4797420 A 1989 CAPLUS
- (2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS
- (3) Silverman; US 5455033 A 1995
- (4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115
- (5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994, P181
- (6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (HIV) infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 CC 18-1 (Animal Nutrition)
 Section cross-reference(s): 14, 15
 AB Humans with HIV infections generally showed .gtoreq.1 abnormally low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally high levels of some micronutrients were also found, but these were attributed to the ingestion of high supplement amts.
 ST micronutrient nutrition human immunodeficiency virus infection; HIV infection diet micronutrient
 IT Carotenes and Carotenoids, biological studies
 Trace elements, biological studies
 Vitamins
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)
 IT Virus, animal
 (human immunodeficiency 1, humans infection by, micronutrient status in relation to)
 IT Nutrients
 (micro-, HIV virus infection in humans in relation to nutritional status of)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 22150-76-1, Biopterin
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)

 L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-HIV activities in existing drugs which are suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan

SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English
 CC 10-5 (Microbial Biochemistry)
 AB Anti-**HIV** activities of 58 com. drugs available for long-term administration without significant side effects were investigated. Lorazepam, Ca hopantenate, prochlorperazine maleate, amantadine HCl, perphenazine (I) and nitrazepam (II) were found to exhibit anti-**HIV** activity in MT-4 cells. But only I and II did so without cytotoxicity. In peripheral blood mononuclear cells, I exhibited only weak anti-**HIV** activity, while II showed none.
 ST AIDS **HIV** virus drug screening perphenazine
 IT Virucides and Virustats
 (for AIDS treatment, screening of)
 IT Immunodeficiency
 (acquired immune deficiency syndrome, perphenazine and other drugs for treatment of)
 IT Virus, animal
 (human immunodeficiency 1, perphenazine and other drugs effect on)
 IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5, Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam 17097-76-6, Calcium hopantenate
 RL: BIOL (Biological study)
 (anti-**HIV** virus activity of, cytotoxicity in relation to)

=> s vitamin d
 162566 VITAMIN
 1998955 D
 L10 21260 VITAMIN D
 (VITAMIN(W)D)

=> s l10 and l8
 L11 33 L10 AND L8

=> d l11 1-33

L11 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:405499 CAPLUS
 DN 139:4715
 TI Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts
 AU Klein, Ulf; Gloghini, Annunziata; Gaidano, Gianluca; Chadburn, Amy; Cesarman, Ethel; Dalla-Favera, Riccardo; Carbone, Antonino
 CS Institute for Cancer Genetics, Columbia University, New York, NY, USA
 SO Blood (2003), 101(10), 4115-4121
 CODEN: BLOOAW; ISSN: 0006-4971
 PB American Society of Hematology
 DT Journal
 LA English
 RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:355828 CAPLUS
 DN 138:363217
 TI Uses of parathyroid hormone antagonists for the diagnosis and treatment of diseases associated with bone mineral loss
 IN Cantor, Thomas L.
 PA USA

SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 928,047.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003087822	A1	20030508	US 2002-215770	20020809
	US 2002160945	A1	20021031	US 2001-928047	20010810
PRAI	US 1999-323606	B2	19990602		
	US 2000-224446P	P	20000810		
	US 2000-224447P	P	20000810		
	US 2000-636530	A2	20000810		
	US 2001-928047	A2	20010810		

L11 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:335643 CAPLUS

DN 138:315894

TI Protein and cDNA sequences of a 11.88-kilodalton human cytochrome P450 CYP27-like protein and their therapeutic uses

IN Mao, Yumin; Xie, Yi

PA Fudan Univ., Peop. Rep. China; Bodao Gene Technology Co., Ltd., Shanghai

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1355304	A	20020626	CN 2000-127547	20001124
PRAI	CN 2000-127547		20001124		

L11 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:301542 CAPLUS

DN 138:286625

TI Relation between micronutrient intakes and CD4 count in HIV infected patients

AU de Luis, D. A.; Bachiller, P.; Aller, R.; de Luis, J.; Izaola, O.; Terroba, M. C.; Cuellar, L.; Sagrado, M. Gonzalez

CS Seccion de Endocrinologia y Nutricion Clinica. Unidad de Apoyo a la Investigacion, Hospital Rio Hortega, Valladolid, 47130, Spain

SO Nutricion Hospitalaria (2002), 17(6), 285-289

CODEN: NUHOEQ; ISSN: 0212-1611

PB Aula Medica Ediciones

DT Journal

LA Spanish

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261603 CAPLUS

DN 138:281598

TI Androstane compounds as androgen receptor (AR) modulators for the treatment of AR-related diseases

IN Wang, Jiabing

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2003026568 A2 20030403 WO 2002-US29436 20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG
PRAI US 2001-324124P P 20010921
OS MARPAT 138:281598

L11 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2003:241921 CAPLUS
DN 138:260539
TI Apparatus and method for flow electroporation of biological samples
IN Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong; Singh, Vininder; Liu,
Linda; Holaday, John W.
PA USA
SO U.S. Pat. Appl. Publ., 59 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003059945	A1	20030327	US 2002-80272	20020221
PRAI	US 2001-269867P	P	20010221		
	US 2001-269868P	P	20010221		

L11 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2003:140661 CAPLUS
TI **HIV**-protease inhibitors impair **vitamin D**
bioactivation to 1,25-dihydroxyvitamin D
AU Cozzolino, Mario; Vidal, Marcos; Arcidiacono, Maria Vittoria; Tebas,
Pablo; Yarasheski, Kevin E.; Dusso, Adriana S.
CS Department of Internal Medicine, Washington University School of Medicine,
St. Louis, MO, 63110, USA
SO AIDS (London, United Kingdom) (2003), 17(4), 513-520
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2002:736060 CAPLUS
DN 137:242163
TI Method and compositions for optimizing blood and tissue stability of
camptothecin and other albumin-binding therapeutic compounds
IN Burke, Thomas G.; Carter, Daniel C.
PA New Century Pharmaceuticals, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074246	A2	20020926	WO 2002-US8301	20020320
	WO 2002074246	A3	20030220		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002193318	A1	20021219	US 2002-101513	20020320
PRAI	US 2001-276908P	P	20010320		

L11 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:696159 CAPLUS
 DN 137:246071
 TI Gene expression profiles relating to normal and osteoarthritic cartilage
 IN Liew, Choong-Chin; Marshall, Wayne E.; Zhang, Hongwei
 PA Chondrogene Inc., Can.
 SO PCT Int. Appl., 777 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070737	A2	20020912	WO 2002-CA247	20020228
	WO 2002070737	C1	20021031		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-271955P	P	20010228		
	US 2001-275017P	P	20010312		
	US 2001-305340P	P	20010713		

L11 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:572142 CAPLUS
 DN 137:257242
 TI Classification of Biologically Active Compounds by Median Partitioning
 AU Godden, Jeffrey W.; Xue, Ling; Bajorath, Juergen
 CS Bothell Research Center (AMRI-BRC), Department of Computer-Aided Drug
 Discovery, Albany Molecular Research Inc. (AMRI), Bothell, WA, 98011, USA
 SO Journal of Chemical Information and Computer Sciences (2002), 42(5),
 1263-1269
 CODEN: JCISD8; ISSN: 0095-2338
 PB American Chemical Society
 DT Journal
 LA English
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2002:483014 CAPLUS
 DN 137:62274
 TI Preparation of potent macrophage activating factors derived from cloned
vitamin D-binding protein and its domain and their
 therapeutic usage for cancer, **HIV** infection and osteopetrosis
 IN Yamamoto, Nobuto
 PA USA
 SO U.S., 24 pp., Cont.-in-part of U. S. 5,620,846.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6410269	B1	20020625	US 1996-618485	19960319
	US 5620846	A	19970415	US 1995-478121	19950607
	CA 2223940	AA	19961219	CA 1996-2223940	19960605
	WO 9640903	A1	19961219	WO 1996-US8867	19960605
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML			
AU	9662535	A1	19961230	AU 1996-62535	19960605
EP	837932	A1	19980429	EP 1996-921279	19960605
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1191567	A	19980826	CN 1996-195808	19960605
	JP 11511962	T2	19991019	JP 1996-501337	19960605
	BR 9609072	A	20001024	BR 1996-9072	19960605
	RU 2198218	C2	20030210	RU 1998-100240	19960605
	US 5712104	A	19980127	US 1997-779729	19970106
	US 5776671	A	19980707	US 1997-938553	19970926
	NO 9705771	A	19980130	NO 1997-5771	19971208
	US 5985545	A	19991116	US 1998-39159	19980313
	US 5998132	A	19991207	US 1999-245755	19990208
	US 2002055140	A1	20020509	US 2001-826463	20010405
PRAI	US 1995-478121	A2	19950607		
	US 1996-618485	A	19960319		
	WO 1996-US8867	W	19960605		
	US 1997-779729	A2	19970106		
	US 1997-938553	A1	19970926		
	US 1998-39159	A1	19980313		

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2002:392665 CAPLUS
 DN 136:364891
 TI Protein and cDNA sequences of a novel human VDUP-1 like protein and
 therapeutical uses
 IN Mao, Yumin; Xie, Yi
 PA Shanghai Shengyuan Gene Development Co., Ltd., Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 37 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1318551	A	20011024	CN 2000-106835	20000419

L11 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2002:242880 CAPLUS
DN 136:395332
TI Accurate partitioning of compounds belonging to diverse activity classes
AU Xue, Ling; Bajorath, Juergen
CS Bothell Research Center, Albany Molecular Research Inc. (AMRI), Bothell,
WA, 98011, USA
SO Journal of Chemical Information and Computer Sciences (2002), 42(3),
757-764
CODEN: JCISD8; ISSN: 0095-2338
PB American Chemical Society
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2001:921220 CAPLUS
DN 136:384820
TI Host genetic background at CCR5 chemokine receptor and vitamin
D receptor loci and human immunodeficiency virus (HIV)
type 1 disease progression among HIV-seropositive injection drug
users
AU Barber, Yolanda; Rubio, Carmen; Fernandez, Elvira; Rubio, Manuel; Fibla,
Joan
CS Departament de Ciencies Mediques Basiques, Lleida, Spain
SO Journal of Infectious Diseases (2001), 184(10), 1279-1288
CODEN: JIDIAQ; ISSN: 0022-1899
PB University of Chicago Press
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2001:319953 CAPLUS
DN 134:337390
TI Synthetic ligand activated transcriptional regulator proteins and their
therapeutic use
IN Barbas, Carlos F.; Kadan, Michael; Beerli, Roger
PA Novartis A.-G., Switz.; The Scripps Research Institute
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030843	A1	20010503	WO 2000-EP10430	20001023
	WO 2001030843	C2	20020919		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1226168	A1	20020731	EP 2000-972849	20001023

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003512827 T2 20030408 JP 2001-533840 20001023
PRAI US 1999-433042 A 19991025
US 2000-586625 A 20000602
WO 2000-EP10430 W 20001023
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2001:115113 CAPLUS

DN 134:163204

TI Synthesis of novel **vitamin D** analogues as
pharmaceutical agents

IN Bretting, Claus Aage Svensgaard

PA Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik
Produktionsaktie, Den.

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010829	A1	20010215	WO 2000-DK389	20000711
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1206448	A1	20020522	EP 2000-943703	20000711
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003506435	T2	20030218	JP 2001-515296	20000711
US 6573255	B1	20030603	US 2002-48363	20020201
PRAI US 1999-147200P	P	19990804		
WO 2000-DK389	W	20000711		

OS MARPAT 134:163204

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2001:6065 CAPLUS

DN 134:37051

TI Method for immune-system strengthening and development of a lipid
transporter for anti-**HIV** and antibacterial gene therapy

IN Worm, Richard; Correa, Michel; Mavoungou, Donatien

PA Can.

SO Fr. Demande, 16 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2792201	A1	20001020	FR 1999-4706	19990415
FR 2792201	B1	20011102		
PRAI FR 1999-4706		19990415		

L11 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:668410 CAPLUS
 DN 133:333809
 TI Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection
 AU Teichmann, Joachim; Stephan, Eva; Discher, Thomas; Lange, Uwe; Federlin, Konrad; Stracke, Hilmar; Friese, Georg; Lohmeyer, Jurgen; Bretzel, Reinhard G.
 CS Medizinische Klinik III und Poliklinik, Justus-Liebig-Universitat Giessen, Giessen, 35385, Germany
 SO Metabolism, Clinical and Experimental (2000), 49(9), 1134-1139
 CODEN: METAAJ; ISSN: 0026-0495
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:178334 CAPLUS
 DN 132:306569
 TI Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype
 AU Kurihara, Noriyoshi; Reddy, Sakamuri V.; Menaa, Cheikh; Anderson, Dirk; Roodman, G. David
 CS Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, 78229, USA
 SO Journal of Clinical Investigation (2000), 105(5), 607-614
 CODEN: JCINAO; ISSN: 0021-9738
 PB American Society for Clinical Investigation
 DT Journal
 LA English
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:161479 CAPLUS
 DN 132:204016
 TI Adenoviral vectors and inducible expression system for gene expression and therapy
 IN Mehtali, Majid; Sorg-guss, Tania
 PA Transgene S.A., Fr.
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012741	A2	20000309	WO 1999-FR2051	19990827
	WO 2000012741	A3	20000504		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2782732	A1	20000303	FR 1998-10842	19980828
	CA 2341775	AA	20000309	CA 1999-2341775	19990827
	AU 9954262	A1	20000321	AU 1999-54262	19990827
	EP 1108051	A2	20010620	EP 1999-940240	19990827
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002523106	T2	20020730	JP 2000-567726	19990827

PRAI FR 1998-10842 A 19980828
WO 1999-FR2051 W 19990827

L11 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1999:722888 CAPLUS
DN 131:332124
TI Arylhydrocarbon receptor ligand antagonists, and therapeutic use
IN Savouret, Jean-Francois; Casper, Robert-Frederic; Milgrom, Edwin
PA Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9956737	A1	19991111	WO 1999-FR1063	19990505
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2778337	A1	19991112	FR 1998-5673	19980505
	FR 2778337	B1	20010831		
	CA 2331364	AA	19991111	CA 1999-2331364	19990505
	AU 9935282	A1	19991123	AU 1999-35282	19990505
	EP 1075256	A1	20010214	EP 1999-916992	19990505
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002513754	T2	20020514	JP 2000-546764	19990505
PRAI	FR 1998-5673	A	19980505		
	WO 1999-FR1063	W	19990505		

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1999:108400 CAPLUS
DN 130:324249
TI Hypocalcemia in HIV infection and AIDS
AU Kuehn, E. W.; Anders, H. J.; Bogner, J. R.; Obermaier, J.; Goebel, F. D.; Schlondorff, D.
CS Medizinische Poliklinik, Ludwig Maximilians University, Munchen, Germany
SO Journal of Internal Medicine (1999), 245(1), 69-73
CODEN: JINMEO; ISSN: 0954-6820
PB Blackwell Science Ltd.
DT Journal
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1998:804189 CAPLUS
DN 130:47474
TI Use of vitamin D compounds to prevent transplant rejection
IN Deluca, Hector F.; Cantorna, Margherita T.; Hullett, Debra A.; Sollinger, Hans W.; Humpal-Winter, Jean; Hayes, Colleen E.
PA Wisconsin Alumni Research Foundation, USA

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855127	A1	19981210	WO 1998-US11558	19980604
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9878172	A1	19981221	AU 1998-78172	19980604
	EP 998290	A1	20000510	EP 1998-926299	19980604
	R:	CH, DE, DK, ES, FR, IT, LI, IE			
	JP 2002510304	T2	20020402	JP 1999-502872	19980604
PRAI	US 1997-870337	A	19970606		
	US 1997-870569	A	19970606		
	WO 1998-US11558	W	19980604		

OS MARPAT 130:47474

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:737133 CAPLUS

DN 130:94374

TI Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis

AU Haug, Charlotte J.; Aukrust, Pal; Haug, Egil; Morkrid, Lars; Muller, Fredrik; Froland, Stig S.

CS Section of Clinical Immunology and Infectious Diseases, Medical Department A, and Research Institute for Internal Medicine, The National Hospital-Rikshospitalet, University of Oslo, Oslo, N-0027, Norway

SO Journal of Clinical Endocrinology and Metabolism (1998), 83(11), 3832-3838
CODEN: JCEMAZ; ISSN: 0021-972X

PB Endocrine Society

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG

US 6350784	B1	20020226	US 1997-824041	19970326
AU 9867718	A1	19981020	AU 1998-67718	19980324
AU 727339	B2	20001207		
BR 9807892	A	20000222	BR 1998-7892	19980324
EP 980203	A1	20000223	EP 1998-913086	19980324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

EE 9900436	A	20000417	EE 1999-436	19980324
NZ 500002	A	20010928	NZ 1998-500002	19980324
JP 2001527541	T2	20011225	JP 1998-545926	19980324
NO 9904639	A	19991124	NO 1999-4639	19990924
MX 9908750	A	20000331	MX 1999-8750	19990924
BG 63612	B1	20020731	BG 1999-103786	19991007

PRAI US 1997-824041 A 19970326
 US 1996-600217 A2 19960212
 US 1996-646988 A2 19960508
 WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:478450 CAPLUS

DN 129:326467

TI Different effect of 1,25-dihydroxyvitamin D3 on replication of
 Mycobacterium avium in monocyte-derived macrophages from human
 immunodeficiency virus-infected subjects and healthy controls

AU Haug, Charlotte J.; Muller, Fredrik; Aukrust, Pal; Froland, Stig S.

CS Medical Department A, Institute for Internal Medicine, Section of Clinical
 Immunology and Infectious Diseases and Research, The National
 Hospital-Rikshospitalet, University of Oslo, Oslo, N-0027, Norway

SO Immunology Letters (1998), 63(2), 107-112

CODEN: IMLED6; ISSN: 0165-2478

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:279452 CAPLUS

DN 129:26703

TI The immunogenetics of human infectious diseases

AU Hill, Adrian V. S.

CS Wellcome Trust Cent. Human Genetics, Univ. Oxford, Oxford, OX3 7BN, UK

SO Annual Review of Immunology (1998), 16, 593-617

CODEN: ARIMDU; ISSN: 0732-0582

PB Annual Reviews Inc.

DT Journal; General Review

LA English

RE.CNT 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:124001 CAPLUS

DN 128:196677

TI Spontaneously dispersible concentrates of sterol esters and
vitamin D derivatives with antiviral and/or
parasitocidal effects

IN Eugster, Carl

PA Marigen S.A., Switz.; Eugster, Carl

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806390	A1	19980219	WO 1996-CH280	19960813
	W: US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 858331	A1	19980819	EP 1996-925634	19960813
	R: DE, FR, GB, IT				
PRAI	WO 1996-CH280		19960813		

OS MARPAT 128:196677

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1997:757910 CAPLUS

DN 128:73688

TI Changes in 1,25-(OH)2D3 synthesis and its receptor expression in spleen
cell subpopulations of mice infected with LPBM5 retrovirus

AU Nguyen, T. M.; Pavlovitch, J.; Papiernik, M.; Guillozo, H.;

Walrant-Debray, O.; Pontoux, C.; Garabedian, M.

CS CNRS, URA 583, Hopital Saint-Vincent de Paul, Univ. Paris V, Paris, 75014,
Fr.

SO Endocrinology (1997), 138(12), 5505-5510

CODEN: ENDOAO; ISSN: 0013-7227

PB Endocrine Society

DT Journal

LA English

L11 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1997:618212 CAPLUS

DN 127:261305

TI A TaqI RFLP in the **vitamin D** receptor gene and its
association with susceptibility to infectious disease with an autoimmune
component

IN Hill, Adrian; Bellamy, Richard; Ruwende, Cyril; Whittle, Hilton; Roy,
Suchismita; Thursz, Mark; Ali, Suleman

PA Isis Innovation Ltd., UK; Hill, Adrian; Bellamy, Richard; Ruwende, Cyril;
Whittle, Hilton; Roy, Suchismita; Thursz, Mark; Ali, Suleman

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9732998	A2	19970912	WO 1997-GB637	19970310
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,				
	VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,				
	GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,				

ML, MR, NE, SN, TD, TG
 AU 9721019 A1 19970922 AU 1997-21019 19970310
 WO 9833938 A1 19980806 WO 1998-GB300 19980130
 W: JP, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 PRAI GB 1996-4985 19960308
 GB 1996-21866 19961021
 GB 1997-1919 19970130
 WO 1997-GB637 19970310

L11 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1997:116550 CAPLUS

DN 126:113175

TI Macrophage-activating factors derived from cloned vitamin D3-binding protein, therapeutic uses, and N-acetylgalactosaminidase detection in disease diagnosis

IN Yamamoto, Nobuto

PA Yamamoto, Nobuto, USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640903	A1	19961219	WO 1996-US8867	19960605
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	US 5620846	A	19970415	US 1995-478121	19950607
	US 6410269	B1	20020625	US 1996-618485	19960319
	AU 9662535	A1	19961230	AU 1996-62535	19960605
	EP 837932	A1	19980429	EP 1996-921279	19960605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11511962	T2	19991019	JP 1996-501337	19960605
	BR 9609072	A	20001024	BR 1996-9072	19960605
	RU 2198218	C2	20030210	RU 1998-100240	19960605
	NO 9705771	A	19980130	NO 1997-5771	19971208
PRAI	US 1995-478121	A	19950607		
	US 1996-618485	A	19960319		
	WO 1996-US8867	W	19960605		

L11 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1996:682599 CAPLUS

DN 126:153113

TI The effect of 1,25-vitamin D3 on maturation of monocytes from HIV -infected patients varies with degree of immunodeficiency

AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S. S.

CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027, Norway

SO APMIS (1996), 104(7-8), 539-548

CODEN: APMSEL; ISSN: 0903-4641

PB Munksgaard

DT Journal

LA English

L11 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1991:22763 CAPLUS
 DN 114:22763
 TI Toxic levels of dietary supplementation in **HIV**-1 infected patients
 AU Fordyce-Baum, M. K.; Mantero-Atienza, E.; Morgan, R.; Van Riel, F.; Beach, R. S.
 CS Sch. Med., Univ. Miami, Miami, FL, USA
 SO Archives of AIDS Research (1990), 4(1-2), 149-57
 CODEN: AARSE9; ISSN: 0899-4811
 DT Journal
 LA English

=> d l11 32 all

L11 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:682599 CAPLUS
 DN 126:153113
 TI The effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected patients varies with degree of immunodeficiency
 AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S. S.
 CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027, Norway
 SO APMIS (1996), 104(7-8), 539-548
 CODEN: APMSEL; ISSN: 0903-4641
 PB Munksgaard
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 AB The active metabolite of **vitamin D**, 1,25-dihydroxyvitamin D3 (1,25D), has been shown to induce monocyte-to-macrophage maturation in vitro as well as monocytic differentiation of bone marrow precursors and monocytic leukemic cell lines. In this study the authors assessed whether 1,25D could improve the maturation defect the authors have previously demonstrated in monocytes from AIDS patients. In vitro growth and maturation of monocytes from 10 controls, 15 asymptomatic **HIV** pos. (CDC group II or III) and 13 symptomatic **HIV** pos. (CDC group IV) was examd. by assessing cellular morphol., differentiation, adherence and protein content. Cells were cultured for 10 days with or without addn. of 1,25D at a concn. of 100 pg/mL. In addn., patients were monitored clin. and by immunol. parameters and **HIV** p24 antigen in serum. The present study showed that addn. of 1,25D significantly improved the growth and maturation in both patient and control groups. There was a significant neg. correlation between response to 1,25D and CD4+ lymphocyte count in blood in **HIV**-infected patients. A greater response to 1,25D was seen in monocytes from patients with advanced immunodeficiency and symptomatic disease than in monocytes from asymptomatic patients. However, in the most advanced cases of **HIV** infection with serious ongoing opportunistic infections the response to 1,25D was very poor, possibly reflecting profound and incorrigible dysfunction of monocytes.
 ST dihydroxyvitamin D3 monocyte macrophage **HIV**1 AIDS
 IT AIDS (disease)
 Human immunodeficiency virus 1
 Immunodeficiency
 Macrophage
 Monocyte
 (effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected humans varies with degree of immunodeficiency)
 IT 32222-06-3, Ro 21-5535

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of 1,25-vitamin D3 on maturation of monocytes from HIV
-infected humans varies with degree of immunodeficiency)

=> d 111 28 all

L11 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:124001 CAPLUS

DN 128:196677

TI Spontaneously dispersible concentrates of sterol esters and
vitamin D derivatives with antiviral and/or
parasitocidal effects

IN Eugster, Carl

PA Marigen S.A., Switz.; Eugster, Carl

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K031-215

ICS A61K031-575; A61K031-59

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806390	A1	19980219	WO 1996-CH280	19960813
	W: US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 858331	A1	19980819	EP 1996-925634	19960813
	R: DE, FR, GB, IT				
PRAI	WO 1996-CH280		19960813		
OS	MARPAT 128:196677				

AB Ultramicroemulsions prepd. from spontaneously dispersible concs. of C2-31 alkyl, C3-31 alkenyl or alkapolyenyl, and retinyl esters of certain sterols and **vitamin D** derivs., together with surfactants and optional solvents, emulsifiers, and coemulsifiers, show antiviral/virucidal and/or parasitocidal (esp. trypanosomicidal) activity. The micellar structure of these esters in the inner oil phase of the emulsions allows them to diffuse through cell membranes into infected cells. Thus, 44 wt.% granules contg. Metolose 90 SH-4000 90.0, Avicel PH-101 80.3, Marigenol conc. (contg. .beta.-sitosteryl palmitate) 134.9, and Aerosil 200 80.3 parts were coated with a mixt. of Marigenol conc. 25 and Aqoat AS-HG enteric delayed-release coating material 31 parts to produce a multiple-unit prepn. An ultramicroemulsion contg. 100 ppm .beta.-sitosteryl palmitate protected MT4 cells (an eternalized T-cell line) from infection with HIV IIIB.

ST virucide sterol **vitamin D** ester; parasiticide sterol **vitamin D** ester; microemulsion sterol **vitamin D** ester

IT Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylphenyl group-terminated, phosphate esters; spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasitocidal effects)

IT Sterols

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(esters; spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasitocidal

effects)

IT Terpenes, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydroxy, esters; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasitocidal
 effects)

IT Protozoacides
 (leishmanicides; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasitocidal
 effects)

IT Drug delivery systems
 (microemulsions; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasitocidal
 effects)

IT Antiviral agents
 Emulsifying agents
 Feline immunodeficiency virus
 Hepatitis B virus
 Human herpesvirus
 Human herpesvirus 5
 Human immunodeficiency virus 1
 Parasitocides
 Trypanosomicides
 (spontaneously dispersible concs. of sterol esters and **vitamin**
D derivs. with antiviral and parasitocidal effects)

IT Alcohols, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (terpenoid, esters; spontaneously dispersible concs. of sterol esters
 and **vitamin D** derivs. with antiviral and
 parasitocidal effects)

IT 601-34-3, Cholesteryl palmitate 1406-16-2D, **Vitamin D**
 , derivs., esters 1908-11-8, Cholesteryl laurate 2308-84-1,
 Stigmasteryl palmitate 2308-85-2, .beta.-Sitosteryl palmitate
 2573-03-7, Cholesteryl arachidate 3177-92-2 3712-16-1,
 .beta.-Sitosteryl oleate 3992-98-1, Ergosteryl palmitate 7726-03-6,
 Cholesteryl valerate 13403-09-3 13403-10-6 20242-97-1, Stigmasteryl
 laurate 22554-56-9 29398-23-0 33249-10-4 34137-25-2,
 .beta.-Sitosteryl stearate 39793-25-4 41005-65-6, .beta.-Sitosteryl
 laurate 41328-97-6, Cholesteryl isovalerate 58380-68-0 59000-65-6
 59015-74-6, .beta.-Sitosteryl arachidate 61192-68-5 80589-29-3
 110026-12-5, Cholestanyl 10-undecenoate 122295-96-9 144338-30-7
 144338-31-8 144338-42-1 144951-98-4 144951-99-5 146513-01-1
 146513-03-3 146513-04-4 146513-07-7 153023-84-8 158180-12-2
 203392-49-8 203392-50-1 203392-51-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (spontaneously dispersible concs. of sterol esters and **vitamin**
D derivs. with antiviral and parasitocidal effects)

IT 106-22-9D, Citronellol, esters with aliph. acids 106-24-1D, Geranyl
 alcohol, esters with aliph. acids 110-27-0, Isopropyl myristate
 142-91-6, Isopropyl palmitate 150-86-7D, esters with aliph. acids
 505-32-8D, esters with aliph. acids 4602-84-0D, Farnesol, esters with
 aliph. acids 6032-29-7, 2-Pentanol 7365-45-9, HEPES 9005-64-5,
 Polyoxyethylenesorbitan monolaurate 9036-19-5 68389-70-8 75621-03-3,
 CHAPS 105362-40-1, Soprochor FL
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (spontaneously dispersible concs. of sterol esters and **vitamin**
D derivs. with antiviral and parasitocidal effects)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ikeda, S; ANTIVIRAL CHEM CHEMOTHER 1994, V5(2), P122 CAPLUS

- (2) Marigen S A Riehen; WO 9221670 A 1992 CAPLUS
 (3) Marigen Sa; WO 9101139 A 1991 CAPLUS
 (4) Marigen Sa; WO 9212989 A 1992 CAPLUS

=> d 111 25 all

L11 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N033-12
 ICS A61K031-14
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6350784	B1	20020226	US 1997-824041	19970326
	AU 9867718	A1	19981020	AU 1998-67718	19980324
	AU 727339	B2	20001207		
	BR 9807892	A	20000222	BR 1998-7892	19980324
	EP 980203	A1	20000223	EP 1998-913086	19980324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900436	A	20000417	EE 1999-436	19980324
	NZ 500002	A	20010928	NZ 1998-500002	19980324
	JP 2001527541	T2	20011225	JP 1998-545926	19980324
	NO 9904639	A	19991124	NO 1999-4639	19990924
	MX 9908750	A	20000331	MX 1999-8750	19990924
	BG 63612	B1	20020731	BG 1999-103786	19991007
PRAI	US 1997-824041	A	19970326		
	US 1996-600217	A2	19960212		
	US 1996-646988	A2	19960508		
	WO 1998-US5792	W	19980324		
AB	An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.				
ST	phytochem nutrient antimicrobial HIV; Echinacea Commiphora phytochem surfactant antimicrobial HIV; folic acid phytochem				

antimicrobial **HIV**

IT Labia
Lip
Lymph node
Lymphatic system
T cell (lymphocyte)
(administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyltrimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyltrimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(amphoteric; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Bacilli
(anaerobic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Allium
Anise
Arctostaphylos
Artemisia
Baptisia
Calendula
Capsicum
Carum
Compositae (Asteraceae)
Coriandrum
Echinacea angustifolia
Echinacea atribactilis
Echinacea pallida
Echinacea purpurea
Echinacea vegetalis
Eucalyptus
Eugenia myrtacea
Gentian (Gentiana)
Inula
Juniper (Juniperus)
Labiatae (Lamiaceae)
Meliosma
Mentha
Mentha aquatica
Myroxylon
Origanum
Parthenium integrifolium
Plantago
Rosemary
Ruta
Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arbovirus
Arenavirus
Bird (Aves)

Cat (*Felis catus*)
 Cattle
Commiphora erythraea
Commiphora molmol
Commiphora myrrha
 Coronavirus
 Cytomegalovirus
 Dog (*Canis familiaris*)
 Drug delivery systems
 Gums and Mucilages
 Horse (*Equus caballus*)
 Human herpesvirus 1
 Human herpesvirus 2
 Human herpesvirus 3
 Human herpesvirus 4
 Human immunodeficiency virus
 Human parainfluenza virus
 Influenza virus
 Livestock
Mycobacterium
 Nutrients
 Papillomavirus
 Picornaviridae
 Rodent
 Sexually transmitted diseases
 Sheep
 Staphylococcus
 Streptococcus
 Surfactants
 Swine
 (antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)
 IT Amides, biological studies
 Anthocyanins
 Enzymes, biological studies
 Natural products, pharmaceutical
 Polyacetylenes, biological studies
 Polysaccharides, biological studies
 Proteins, general, biological studies
 Sesquiterpenes
 Tannins
 Vitamins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)
 IT Encephalitis
 Meningitis
 (bacterial and viral; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)
 IT Detergents
 Surfactants
 (cationic; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)
 IT Inflammation
 (cellulitis; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)
 IT Polyacetylenes, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
 (mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
 (nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
 (periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
 (phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
 (rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
 (zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid,

biological studies 57-88-5, Cholesterol, biological studies 58-86-6,
 Xylose, biological studies 59-23-4, Galactose, biological studies
 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological
 studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid,
 biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate
 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol
 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5,
 Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2,
 Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic
 acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2,
 Cumin aldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9,
 Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5,
 Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4,
 Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9,
 Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5,
 .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3,
 Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid
 536-60-7, Cumic alcohol 548-75-4, Quercetagenin-7-glucoside 563-83-7
 593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone
 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6,
 Caryophyllene epoxide 1406-16-2, **Vitamin D**
 1406-18-4, Vitamin E 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5,
 Pontica epoxide 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological
 studies 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4,
 4-O-Methylglucuronic acid 5373-11-5, Luteolin-7-glucoside 5937-48-4,
 3-epi-.alpha.-Amyrin 6537-80-0, Chicoric acid 6556-12-3, Glucuronic
 acid 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies
 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese,
 biological studies 7440-09-7, Potassium, biological studies 7440-23-5,
 Sodium, biological studies 7440-48-4, Cobalt, biological studies
 7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus, biological
 studies 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronarabinoxylan
 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
 biological studies 16887-00-6, Chloride, biological studies
 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
 Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0
 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
 69350-61-4, Epishyobunol 74282-22-7 75081-19-5, Pentadecadiene
 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
 125199-93-1 148879-89-4, Commiphoric acid 149531-55-5,
 .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
 .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7,
 Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium

chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium
chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(complex; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Bryant; US 4797420 A 1989 CAPLUS

(2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS

(3) Silverman; US 5455033 A 1995

(4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and
Related Remedies", 3rd Edition 1993, P115

(5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994,
P181

(6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

=> d l11 22 all

L11 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1999:108400 CAPLUS

DN 130:324249

TI Hypocalcemia in **HIV** infection and AIDS

AU Kuehn, E. W.; Anders, H. J.; Bogner, J. R.; Obermaier, J.; Goebel, F. D.;
Schlondorff, D.

CS Medizinische Poliklinik, Ludwig Maximilians University, Munchen, Germany

SO Journal of Internal Medicine (1999), 245(1), 69-73

CODEN: JINMEO; ISSN: 0954-6820

PB Blackwell Science Ltd.

DT Journal

LA English

CC 15-8 (Immunochemistry)

AB The objective here was to study the prevalence and possible mechanisms of
hypocalcemia in **HIV** infection and AIDS in 828 patients with
HIV infection or AIDS and 549 controls. Measured were total serum
calcium and albumin levels. Parameters of calcium homeostasis were detd.
in a subgroup of 21 hypocalcemic AIDS patients. Mean serum calcium was
2.34 mmol L-1 in the **HIV** group vs. 2.46 mmol L-1 in controls.
After adjusting for serum albumin, hypocalcemia was present in 6.5% of the
HIV group vs. 1.1% of controls. Mean serum calcium was declining
according to CDC groups, and differed from controls in each group.
Regression coeffs. of calcium vs. albumin were 0.147 amongst **HIV**
-infected patients and 0.106 for controls. In the subgroup of
hypocalcemic patients with AIDS, 10/21 had **vitamin D**
deficiency, 6 of these with low ionized calcium levels. Low serum PTH was
found in 2/21 patients, magnesium deficiency in 1/21. Of the remaining 8
patients, only 1 had secondary hyperparathyroidism, while the other 7
lacked an adequate PTH response, despite low ionized calcium levels in 4
subjects. Mean serum calcium concns. were lower through all CDC stages,
irresp. of albumin, resulting in a higher prevalence of hypocalcemia in
HIV-pos. patients compared with controls. In a considerable no.,

this seems to be caused by **vitamin D** deficiency and potentially a lack of adequate PTH secretion.

ST hypocalcemia **HIV** infection AIDS

IT AIDS (disease)

Human immunodeficiency virus 1

Hypoparathyroidism

(hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

IT 1406-16-2, **Vitamin D** 7439-95-4, Magnesium, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (deficiency; hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

IT 9002-64-6, Parathyroid hormone

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

IT 7440-70-2, Calcium, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (hypocalcemia; hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Brezis, M; Miner Electrolyte Metab 1982, V8, P307 MEDLINE
- (2) Brown, L; Endocrinol Metab Clin North Am 1991, V20, P655
- (3) Coodley, G; AIDS 1993, V7, P1595 MEDLINE
- (4) Coodley, G; J Acquir Immune Defic Syndr 1994, V7, P681 MEDLINE
- (5) Croxson, T; J Clin Endocrinol Metab 1989, V68, P317 MEDLINE
- (6) Desai, T; Am J Med 1988, V84, P209 MEDLINE
- (7) Dobs, A; Am J Med 1988, V84, P611 MEDLINE
- (8) Freedman, D; Br Med J 1982, V284, P700 MEDLINE
- (9) Glassoc, R; Ann Intern Med 1992, V112, P35
- (10) Grinspoon, S; N Engl J Med 1992, V327, P1360 CAPLUS
- (11) Haug, C; J Infect Dis 1994, V169, P889 MEDLINE
- (12) Hellman, P; AIDS Res Hum Retroviruses 1994, V10, P391 MEDLINE
- (13) Hellman, P; Surgery 1996, V120, P985 MEDLINE
- (14) Horwitz, C; Am J Med 1972, V52, P797 MEDLINE
- (15) Jacobsen, M; J Clin Endocrinol Metab 1991, V72, P1130
- (16) Jaeger, P; J Clin Endocrinol Metab 1994, V79, P1701 CAPLUS
- (17) Lebowitz, M; Semin Nephrol 1992, V12, P146 MEDLINE
- (18) Lecatasa, G; Proc Soc Exp Biol Med 1984, V178, P653
- (19) Lehmann, R; Horm Res 1994, V42, P295 CAPLUS
- (20) Li, Y; J Clin Invest 1996, V97, P889
- (21) Macher, A; N Engl J Med 1983, V309, P1454 MEDLINE
- (22) Membreno, L; J Clin Endocrinol Metab 1987, V65, P482 MEDLINE
- (23) Neufeld, M; Medicine 1981, V60, P355 MEDLINE
- (24) Payne, R; Br Med J 1973, V4, P643 MEDLINE
- (25) Perazella, M; J Gen Intern Med 1994, V9, P232 MEDLINE
- (26) Peter, S; J Natl Med Assoc 1991, V83, P889 MEDLINE
- (27) Peter, S; J Natl Med Assoc 1992, V84, P626 MEDLINE
- (28) Poretsky, L; Mt Sinai J Med 1990, V57, P236 MEDLINE
- (29) Raffi, F; AIDS 1991, V5, P729 MEDLINE
- (30) Stein, T; Metabolism 1990, V39, P876 MEDLINE
- (31) Strauss, K; Arch Intern Med 1991, V151, P1441 MEDLINE
- (32) Welch, K; JAMA 1984, V252, P1152 MEDLINE
- (33) Zaloga, G; Ann Intern Med 1987, V107, P36 MEDLINE

(34) Zaloga, G; Crit Care Med 1992, V20, P251 MEDLINE

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

=> d 19 6-8

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG

US 6350784	B1	20020226	US 1997-824041	19970326
AU 9867718	A1	19981020	AU 1998-67718	19980324
AU 727339	B2	20001207		
BR 9807892	A	20000222	BR 1998-7892	19980324
EP 980203	A1	20000223	EP 1998-913086	19980324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

EE 9900436	A	20000417	EE 1999-436	19980324
NZ 500002	A	20010928	NZ 1998-500002	19980324
JP 2001527541	T2	20011225	JP 1998-545926	19980324
NO 9904639	A	19991124	NO 1999-4639	19990924
MX 9908750	A	20000331	MX 1999-8750	19990924
BG 63612	B1	20020731	BG 1999-103786	19991007

PRAI US 1997-824041 A 19970326
 US 1996-600217 A2 19960212
 US 1996-646988 A2 19960508
 WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (HIV)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-HIV activities in existing drugs which are
 suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan
 SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English

=> d 19 8 all

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-HIV activities in existing drugs which are
 suitable for long-term oral administration.
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan

SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English
 CC 10-5 (Microbial Biochemistry)
 AB Anti-**HIV** activities of 58 com. drugs available for long-term administration without significant side effects were investigated. Lorazepam, Ca hopantenate, prochlorperazine maleate, amantadine HCl, perphenazine (I) and nitrazepam (II) were found to exhibit anti-**HIV** activity in MT-4 cells. But only I and II did so without cytotoxicity. In peripheral blood mononuclear cells, I exhibited only weak anti-**HIV** activity, while II showed none.
 ST AIDS **HIV** virus drug screening perphenazine
 IT Virucides and Virustats
 (for AIDS treatment, screening of)
 IT Immunodeficiency
 (acquired immune deficiency syndrome, perphenazine and other drugs for treatment of)
 IT Virus, animal
 (human immunodeficiency 1, perphenazine and other drugs effect on)
 IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5, Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam **17097-76-6**, Calcium hopantenate
 RL: BIOL (Biological study)
 (anti-**HIV** virus activity of, cytotoxicity in relation to)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	93.70	125.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4
 DICTIONARY FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> S 17097-76-6/RN

L12 1 17097-76-6/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L12 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 5.63 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 17097-76-6 REGISTRY

CN Butanoic acid, 4-[[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]amino]-,
calcium salt (2:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butanoic acid, 4-[(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)amino]-, calcium
salt (2:1), (R)-

CN Butyric acid, 4-(2,4-dihydroxy-3,3-dimethylbutyramido)-, calcium salt
(2:1), D-(+)- (8CI)

OTHER NAMES:

CN Calcium D-(+)-homopantothenate

CN Calcium D-homopantothenate

CN Calcium homopantothenate

CN Calcium hopantenate

CN D-(+)-Homopantothenic acid calcium salt

CN Hopantenate calcium

CN Pantogam

CN Vivant

FS STEREOSEARCH


MF C10 H19 N O5 . 1/2 Ca

CI COM

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU,
EMBASE, IPA, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN
(*File contains numerically searchable property data)

CRN (18679-90-8)

Absolute stereochemistry.



● 1/2 Ca

115 REFERENCES IN FILE CA (1957 TO DATE)

115 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.68	128.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.21

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2003 VOL 139 ISS 2
FILE LAST UPDATED: 6 Jul 2003 (20030706/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

=> s 12

L13 5412 L2

=> s 13

L14 11658 L3

=> s 113 and 18

L15 4 L13 AND L8

=> d 115 1-4

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2002:745859 CAPLUS

DN 137:277454

TI A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis

AU Sambandamurthy, Vasan K.; Wang, Xiaojuan; Chen, Bing; Russell, Robert G.; Derrick, Steven; Collins, Frank M.; Morris, Sheldon L.; Jacobs, William R.

CS Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY, USA

SO Nature Medicine (New York, NY, United States) (2002), 8(10), 1171-1174
CODEN: NAMEFI; ISSN: 1078-8956

PB Nature Publishing Group

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2001:6065 CAPLUS

DN 134:37051

TI Method for immune-system strengthening and development of a lipid transporter for anti-HIV and antibacterial gene therapy

IN Worm, Richard; Correa, Michel; Mavoungou, Donatien

PA Can.

SO Fr. Demande, 16 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2792201	A1	20001020	FR 1999-4706	19990415
	FR 2792201	B1	20011102		
PRAI	FR 1999-4706		19990415		

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI WO 9842188 A1 19981001 WO 1998-US5792 19980324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG
US 6350784 B1 20020226 US 1997-824041 19970326
AU 9867718 A1 19981020 AU 1998-67718 19980324
AU 727339 B2 20001207
BR 9807892 A 20000222 BR 1998-7892 19980324
EP 980203 A1 20000223 EP 1998-913086 19980324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
EE 9900436 A 20000417 EE 1999-436 19980324
NZ 500002 A 20010928 NZ 1998-500002 19980324
JP 2001527541 T2 20011225 JP 1998-545926 19980324
NO 9904639 A 19991124 NO 1999-4639 19990924
MX 9908750 A 20000331 MX 1999-8750 19990924
BG 63612 B1 20020731 BG 1999-103786 19991007
PRAI US 1997-824041 A 19970326
US 1996-600217 A2 19960212
US 1996-646988 A2 19960508
WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (HIV)
infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English

=> d 115 3 4 all

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1998:661494 CAPLUS
DN 129:298375
TI Antimicrobial prevention and treatment of human immunodeficiency virus and
other infectious diseases
IN Squires, Meryl
PA USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A01N033-12
ICS A61K031-14
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6350784	B1	20020226	US 1997-824041	19970326
	AU 9867718	A1	19981020	AU 1998-67718	19980324
	AU 727339	B2	20001207		
	BR 9807892	A	20000222	BR 1998-7892	19980324
	EP 980203	A1	20000223	EP 1998-913086	19980324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900436	A	20000417	EE 1999-436	19980324
	NZ 500002	A	20010928	NZ 1998-500002	19980324
	JP 2001527541	T2	20011225	JP 1998-545926	19980324
	NO 9904639	A	19991124	NO 1999-4639	19990924
	MX 9908750	A	20000331	MX 1999-8750	19990924
	BG 63612	B1	20020731	BG 1999-103786	19991007
PRAI	US 1997-824041	A	19970326		
	US 1996-600217	A2	19960212		
	US 1996-646988	A2	19960508		
	WO 1998-US5792	W	19980324		
AB	An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.				
ST	phytochem nutrient antimicrobial HIV; Echinacea Commiphora phytochem surfactant antimicrobial HIV; folic acid phytochem antimicrobial HIV				
IT	Labia Lip Lymph node Lymphatic system T cell (lymphocyte) (administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Quaternary ammonium compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyl dimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Quaternary ammonium compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzyl dimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Surfactants (amphoteric; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Bacilli (anaerobic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				
IT	Allium				

Anise
 Arctostaphylos
 Artemisia
 Baptisia
 Calendula
 Capsicum
 Carum
 Compositae (Asteraceae)
 Coriandrum
 Echinacea angustifolia
 Echinacea atribactilus
 Echinacea pallida
 Echinacea purpurea
 Echinacea vegetalis
 Eucalyptus
 Eugenia mytacea
 Gentian (Gentiana)
 Inula
 Juniper (Juniperus)
 Labiatae (Lamiaceae)
 Meliosma
 Mentha
 Mentha aquatica hypeuria
 Myroxylon
 Origanum
 Parthenium integrifolium
 Plantago
 Rosemary
 Ruta
 Sage (Salvia)
 (antimicrobial isolates of; antimicrobial prevention and treatment of
 human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
 Antibacterial agents
 Antimicrobial agents
 Antiviral agents
 Arbovirus
 Arenavirus
 Bird (Aves)
 Cat (Felis catus)
 Cattle
 Commiphora erythraea
 Commiphora molmol
 Commiphora myrrha
 Coronavirus
 Cytomegalovirus
 Dog (Canis familiaris)
 Drug delivery systems
 Gums and Mucilages
 Horse (Equus caballus)
 Human herpesvirus 1
 Human herpesvirus 2
 Human herpesvirus 3
 Human herpesvirus 4
 Human immunodeficiency virus
 Human parainfluenza virus
 Influenza virus
 Livestock
 Mycobacterium
 Nutrients
 Papillomavirus
 Picornaviridae

Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis
(bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
Surfactants
(cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
(cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
(mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(opthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid 536-60-7, Cumic alcohol 548-75-4, Quercetagenin-7-glucoside 563-83-7 593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6, Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies

3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus, biological studies 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs. 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronarabinoxylan 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate, biological studies 16887-00-6, Chloride, biological studies 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1, 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9, Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7 69350-61-4, Epishyobunol 74282-22-7 75081-19-5, Pentadecadiene 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3 125199-93-1 148879-89-4, Commiphoric acid 149531-55-5, .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5, .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7, Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5, Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(complex; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bryant; US 4797420 A 1989 CAPLUS
- (2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS
- (3) Silverman; US 5455033 A 1995
- (4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115

- (5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994, P181
 (6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (HIV) infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 CC 18-1 (Animal Nutrition)
 Section cross-reference(s): 14, 15
 AB Humans with HIV infections generally showed .gtoreq.1 abnormally low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally high levels of some micronutrients were also found, but these were attributed to the ingestion of high supplement amts.
 ST micronutrient nutrition human immunodeficiency virus infection; HIV infection diet micronutrient
 IT Carotenes and Carotenoids, biological studies
 Trace elements, biological studies
 Vitamins
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)
 IT Virus, animal
 (human immunodeficiency 1, humans infection by; micronutrient status in relation to)
 IT Nutrients
 (micro-, HIV virus infection in humans in relation to nutritional status of)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 22150-76-1, Biopterin
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)

=> s l14 an dl8

MISSING OPERATOR L14 AN

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l14 and l8

L8 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l14 and l8

L16 19 L14 AND L8

=> s 116 not 115
L17 15 L16 NOT L15

=> d 117 1-15

L17 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2003:205993 CAPLUS
DN 138:268107
TI Nicotinamide: An oral antimicrobial agent with activity against both
Mycobacterium tuberculosis and human immunodeficiency virus
AU Murray, Michael F.
CS Department of Medicine, Brigham and Women's Hospital, Harvard University,
Boston, MA, USA
SO Clinical Infectious Diseases (2003), 36(4), 453-460
CODEN: CIDIEL; ISSN: 1058-4838
PB University of Chicago Press
DT Journal; General Review
LA English
RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2003:154399 CAPLUS
DN 138:204936
TI Preparation of heterocyclic compds. as integrase inhibiting antiviral
agents
IN Kiyama, Ryuichi; Kanda, Yasuhiko; Tada, Yukio; Fujishita, Toshio;
Kawasuji, Takashi; Takechi, Shozo; Fuji, Masahiro
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 663 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016275	A1	20030227	WO 2002-JP8108	20020808
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
	UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				

PRAI JP 2001-245071 A 20010810
JP 2001-370860 A 20011205
JP 2002-191483 A 20020628

OS MARPAT 138:204936

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2002:657938 CAPLUS
DN 137:190753
TI Transdermal therapeutic system containing testosterone and method for the
production
IN Theobald, Frank

PA LTS Lohmann Therapie-Systeme A.-G., Germany
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066018	A2	20020829	WO 2002-EP1258	20020207
	WO 2002066018	A3	20030424		
	W:	AU, BR, CA, CN, JP, KR, MX, US, ZA			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
	DE 10107663	A1	20020905	DE 2001-10107663	20010219
PRAI	DE 2001-10107663	A	20010219		

L17 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51504 CAPLUS

DN 136:112623

TI Zinc finger motif sequences from herpes simplex virus protein IE63 and uses thereof in drug screening for treating herpesvirus infection

IN Clements, John Barklie; MacLean, Alasdair Roderick

PA The University Court of the University of Glasgow, UK

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004492	A2	20020117	WO 2001-GB3114	20010711
	WO 2002004492	A3	20020510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1299725	A2	20030409	EP 2001-949666	20010711
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	GB 2000-16890	A	20000711		
	WO 2001-GB3114	W	20010711		

L17 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 2001:504998 CAPLUS

DN 136:273127

TI Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide

AU Murray, M. F.; Langan, M.; MacGregor, R. R.

CS Department of Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA

SO Nutrition (New York, NY, United States) (2001), 17(7/8), 654-656

CODEN: NUTRER; ISSN: 0899-9007

PB Elsevier Science Inc.

DT Journal
LA English

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1999:454270 CAPLUS

DN 131:82943

TI Compositions and methods for identifying therapeutic agents and for treating cells having double minute DNA

IN Wahl, Geoffrey M.; Shepard, H. Michael; Shimizu, Noriaki

PA Newbiotics, Inc., USA; The Salk Institute; Kanda, Teru

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935292	A1	19990715	WO 1999-US601	19990111
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2318380	AA	19990715	CA 1999-2318380	19990111
	AU 9922217	A1	19990726	AU 1999-22217	19990111
	EP 1070140	A1	20010124	EP 1999-902175	19990111
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9906926	A	20020115	BR 1999-6926	19990111
	JP 2002510033	T2	20020402	JP 2000-527673	19990111
PRAI	US 1998-71146P	P	19980112		
	US 1998-77644P	P	19980311		
	WO 1999-US601	W	19990111		

OS MARPAT 131:82943

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1997:606368 CAPLUS

DN 127:272289

TI Apoptotic DNA fragmentation, and its in vitro prevention by nicotinamide, in lymphocytes from HIV-1-seropositive patients and in HIV-1-infected MT-4 cells

AU Savarino, A.; Martini, C.; Orofino, G. C.; Cantamessa, C.; Castelli, L.; Pich, P. G.; Sinicco, A.; Pugliese, A.

CS Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Turin, Italy

SO Cell Biochemistry and Function (1997), 15(3), 171-179

CODEN: CBFUDH; ISSN: 0263-6484

PB Wiley

DT Journal

LA English

L17 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1997:79334 CAPLUS

DN 126:143042

TI Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1

AU Savarino, A.; Pugliese, A.; Martini, C.; Pich, P. G.; Pescarmona, G. P.; Malavasi, F.

CS Department of Medical and Surgical Sciences, University of Torino, Turin, Italy
 SO Journal of Biological Regulators and Homeostatic Agents (1996), 10(1), 13-18
 CODEN: JBRAER; ISSN: 0393-974X
 PB Wichtig
 DT Journal
 LA English

L17 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1996:256739 CAPLUS

DN 124:299031

TI Growth control for cells encapsulated within bioartificial organs

IN Schinstine, Malcolm; Shoichet, Molly S.; Gentile, Frank T.; Hammang, Joseph P.; Holland, Laura M.; Cain, Brian M.; Doherty, Edward J.; Winn, Shelley R.; Aebischer, Patrick

PA Cytotherapeutics, Inc., USA

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9602646	A2	19960201	WO 1995-US9281	19950720
	WO 9602646	A3	19960517		
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5935849	A	19990810	US 1994-279773	19940720
	US 5843431	A	19981201	US 1995-432698	19950509
	AU 9531422	A1	19960216	AU 1995-31422	19950720
	AU 698624	B2	19981105		
	EP 771350	A1	19970507	EP 1995-927373	19950720
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
	JP 10506266	T2	19980623	JP 1995-505271	19950720
	BR 9508312	A	19990601	BR 1995-8312	19950720
	NO 9700156	A	19970320	NO 1997-156	19970114
	FI 9700217	A	19970117	FI 1997-217	19970117
PRAI	US 1994-279773	A	19940720		
	US 1995-432698	A	19950509		
	WO 1995-US9281	W	19950720		

L17 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1995:958459 CAPLUS

DN 124:7065

TI Biochemically active agents for chemical catalysis and cell receptor activation

IN Kossovsky, Nir; Sponsler, Edward; Gelman, Andrew; Rajguru, Samir

PA The Regents of the University of California, USA

SO U.S., 13 pp. Cont.-in-part of U.S. 5,334,394.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5460830	A	19951024	US 1993-145870	19931101

US 5219577	A	19930615	US 1990-542255	19900622
US 5178882	A	19930112	US 1991-690601	19910424
JP 05255111	A2	19931005	JP 1991-178805	19910624
JP 2932406	B2	19990809		
US 5334394	A	19940802	US 1993-199	19930104
US 5462750	A	19951031	US 1994-225100	19940408
WO 9512392	A1	19950511	WO 1994-US12515	19941031
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2174244	AA	19950511	CA 1994-2174244	19941031
EP 726767	A1	19960821	EP 1995-901094	19941031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09504790	T2	19970513	JP 1994-513349	19941031
PRAI US 1990-542255		19900622		
US 1991-690601		19910424		
US 1993-199		19930104		
US 1993-986		19930106		
US 1993-145870		19931101		
US 1993-146536		19931101		
US 1993-147751		19931104		
WO 1994-US12515		19941031		

L17 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1995:673568 CAPLUS

DN 123:109959

TI **HIV** infection decreases intracellular nicotinamide adenine dinucleotide [NAD]

AU Murray, Michael F.; Nghiem, Michael; Srinivasan, Alagarsamy

CS Dep. Med., Univ. PA Sch. Med., Philadelphia, PA, USA

SO Biochemical and Biophysical Research Communications (1995), 212(1), 126-31
CODEN: BBRCA9; ISSN: 0006-291X

PB Academic

DT Journal

LA English

L17 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1995:590755 CAPLUS

DN 123:357

TI Nicotinamide inhibits **HIV**-1 in both acute and chronic in vitro infection

AU Murray, Michael F.; Srinivasan, Alagarsamy

CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama

SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X

PB Academic

DT Journal

LA English

L17 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 1995:556533 CAPLUS

DN 123:143841

TI Synthesis and antiviral evaluation of fluorinated dipyridodiazepinones and dipyridodiazepines (nevirapine derivatives)

AU Boyode, B. P.; Sinet, M.; Barese, A.; Forestier-Roux, M.-A.; Condom, R.; Ayi, I. A.; Kirn, A.; Moog, C.; Guedj, R.

CS Faculte Sciences, Universite Nice-Sophia Antipolis, Nice, F-06108, Fr.

SO Antiviral Chemistry & Chemotherapy (1995), 6(3), 162-8
CODEN: ACCHEH; ISSN: 0956-3202

PB Blackwell

DT Journal

LA English

L17 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:622844 CAPLUS
 DN 115:222844
 TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of HIV infection
 AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
 CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
 SO Voprosy Virusologii (1991), 36(3), 216-18
 CODEN: VVIRAT; ISSN: 0507-4088
 DT Journal
 LA Russian

L17 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8904314	A1	19890518	WO 1988-NL48	19881102
	W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU				
	RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
	AU 8826199	A1	19890601	AU 1988-26199	19881102
	JP 02502096	T2	19900712	JP 1988-508750	19881102
	FI 8903279	A	19890705	FI 1989-3279	19890705
PRAI	IL 1987-84387		19871106		
	WO 1988-NL48		19881102		
OS	MARPAT 112:151841				

=> d 117 15 all

L17 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 IC ICM C07F009-10
 ICS C07F009-09; C07F009-58; A61K031-66
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 27

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

WO 8904314	A1	19890518	WO 1988-NL48	19881102
W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU				
RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
AU 8826199	A1	19890601	AU 1988-26199	19881102
JP 02502096	T2	19900712	JP 1988-508750	19881102
FI 8903279	A	19890705	FI 1989-3279	19890705
PRAI IL 1987-84387		19871106		
WO 1988-NL48		19881102		

OS MARPAT 112:151841

AB The acylglycerophosphate esters R1OCH2CH(OR2)CH2OP(O)(O-)GAzR3 [R1, R2 = H, fatty acyl; A = CH2, polymethylene, oxapolyethylene, thiapolyethylene, etc. R3 = (un)substituted Ph or pyridinium, etc.; G = O, S; Z = 0, 1-18] are prepd. as virucides, suitable for treating human immunodeficiency virus (HIV) infections. 2-Hydroxyethyl-1-nicotinamide chloride (prepn. given) was transphosphatidylated enzymically, by the method of Eibel and Kovatchev (1981), to give phosphatidyl-2-hydroxyethyl-1-nicotinamide (I). I (20 .mu.g/mL) totally controlled HIV, in vitro, as shown by the method of Moore, et al. (1978).

ST virucide animal phospholipid; glycerophosphate deriv prepn AIDS drug

IT Phosphatidylethanolamines
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetylation of)

IT Phospholipids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(virucides, animal)

IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, with reaction products of acylglycerophosphates with alcs. and thiols)

IT Phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(esters, prepn. of, as animal virucides)

IT Virucides and Virustats
(medical, reaction products of acid glycerophosphates with alcs. or thiols)

IT Phosphatidylethanolamines
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction products, with acetic anhydride, prepn. of, as animal virucide)

IT 98-92-0, Nicotinamide
RL: BIOL (Biological study)
(condensation of, with chloroethanol)

IT 107-07-3, 2-Chloroethanol, biological studies
RL: BIOL (Biological study)
(condensation of, with nicotinamide).

IT 126235-31-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and transphosphatidylation of)

IT 58-27-5DP, reaction products with phosphatidylethanolamines 100-51-6DP, Benzenemethanol, reaction products with phosphatidic acids 108-24-7DP, reaction products with phosphatidylethanolamines 141-79-7DP, reaction products with phosphatidylethanolamines 126235-31-2DP, reaction products with phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as animal virucide)

IT 58-27-5, Menadione
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phosphatidylethanolamine)

=> d 117 14 all

L17 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 1991:622844 CAPLUS
DN 115:222844
TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Voprosy Virusologii (1991), 36(3), 216-18
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian
CC 1-5 (Pharmacology)
AB The antiviral effects of arom. carbonic acid amides including trisubstituted benzamides and nicotinamide were tested in lymphoblastoid cells infected with **HIV** virus. Five out of 8 substances tested had an antiviral activity which might be due to their capacity to inhibit ADP-ribosylation. By blocking ADP-ribosylation, the substances depressed DNA capacity for reparation, inhibited differentiation and transformation of cells, and had indirect effects on the reprod. of viruses. The universal nature of the processes of NAD⁺-dependent ADP-ribosylation suggests that the range of antiviral activity of inhibitors of mono- and poly-ADP-ribosylation may not be limited only to **HIV** infection.
ST immunodeficiency virus benzamide deriv virucide ribosylation
IT Virucides and Virustats
(benzamide derivs. as, on immunodeficiency virus, ADP-ribosylation inhibition in)
IT Glycosidation
(ADP-ribosidation, benzamide derivs. virucidal effects in relation to inhibition of)
IT Virus, animal
(human immunodeficiency 1, benzamide derivs. inhibition of, ADP-ribosylation in)
IT 55-21-0, Benzamide **98-92-0**, 3-Pyridinecarboxamide 645-09-0, 3-Nitrobenzamide 3544-24-9, 3-Aminobenzamide 5813-86-5, 3-Methoxybenzamide 58202-87-2 137084-97-0 137084-98-1
RL: PRP (Properties)
(virucidal effects of, on immunodeficiency virus, ADP-ribosylation inhibition in)

=> d 117 12 all

L17 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 1995:590755 CAPLUS
DN 123:357
TI Nicotinamide inhibits **HIV**-1 in both acute and chronic in vitro infection
AU Murray, Michael F.; Srinivasan, Alagarsamy
CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic
DT Journal
LA English
CC 1-5 (Pharmacology)
AB **HIV**-1 infected patients can manifest a no. of poorly understood conditions including dermatitis, dementia, and diarrhea. These conditions are in some ways suggestive of pellagra, the syndrome assocd. with niacin

depletion. We demonstrate here that nicotinamide, the amide form of niacin, inhibits **HIV-1** infection in cell culture. Neither nicotinic acid which is the alternative form of niacin, nor thiamine (another B complex vitamin), shows a similar degree of inhibition in tissue culture. This inhibition occurs in both primary cells and in established cell lines. In vitro models of acute and chronic **HIV** infection are demonstrated here to be inhibited by nicotinamide in a dose dependent manner when added in millimolar concns.

ST nicotinamide HIV1 infection inhibition
IT Virucides and Virustats
 (nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection)
IT Virus, animal
 (human immunodeficiency 1, nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection)
IT **98-92-0**, Nicotinamide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of **HIV-1** in acute and chronic in vitro infection by)
IT 59-43-8, Thiamine, biological studies 59-67-6, Nicotinic acid, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection comparison with)

=> s herpes or hsv or hhsv or cmv

21482 HERPES

9575 HSV

0 HHSV

5388 CMV

L18 27587 HERPES OR HSV OR HHSV OR CMV

=> s l18 and l8

L19 2073 L18 AND L8

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID

L2 2 S VITAMIN B5

L3 2 S VITAMIN B3

L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1

E RETROVIRAL

L6 13948 S E1-E6

L7 50063 S HIV

L8 61642 S L7 OR L6

L9 8 S L5 AND L8

L10 21260 S VITAMIN D

L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN

SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8

=> s l18 and l5

L20 6 L18 AND L5

=> d l20 1-6

L20 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2003:93061 CAPLUS

DN 138:142477

TI Drug composition containing amino acids and Vitamin C for the prevention of angina pectoris

IN Sibbe, Bernhard; Wiehrer, Walter

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10128934	A1	20030206	DE 2001-10128934	20010618
PRAI	DE 2001-10128934		20010618		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2002:928122 CAPLUS

DN 138:12504

TI Method for assaying biomolecules and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques

IN Smith, Jack V.

PA USA

SO U.S. Pat. Appl. Publ., 46 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002182600	A1	20021205	US 2001-829563	20010411
PRAI	US 2001-829563		20010411		

L20 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 1998:293397 CAPLUS

DN 128:326546

TI Methods and compositions for dietary supplementation

IN Burgstiner, Carson B.

PA Burgstiner, Jacqueline Cook, USA

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818491	A1	19980507	WO 1997-US19564	19971028
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1996-29403P	P	19961028		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1996:370862 CAPLUS
DN 125:57030
TI Effects of B vitamin injection on bovine herpesvirus-1 infection and immunity in feed-restricted beef calves
AU Dubeski, P. L.; d'Offay, J. M.; Owens, F. N.; Gill, D. R.
CS Department Animal Science, Oklahoma State University, Stillwater, OK, 74078-0425, USA
SO Journal of Animal Science (1996), 74(6), 1367-1374
CODEN: JANSAG; ISSN: 0021-8812
PB American Society of Animal Science
DT Journal
LA English

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1986:45751 CAPLUS
DN 104:45751
TI Antiviral pharmaceutical preparations and their use
IN Haines, Harold Gray; Dickens, Caroline Burgess
PA Brigham, Dana, USA
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 154344	A2	19850911	EP 1985-102607	19850307
	EP 154344	A3	19900613		
	EP 154344	B1	19930707		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US	4628063	A	19861209	US 1984-587398	19840308
WO	8503862	A1	19850912	WO 1985-US362	19850306
	W: AU, BR, DK, FI, HU, JP, NO				
AU	8540673	A1	19850924	AU 1985-40673	19850306
AU	571072	B2	19880331		
JP	61501325	T2	19860703	JP 1985-501264	19850306
JP	06076317	B4	19940928		
IL	74535	A1	19881230	IL 1985-74535	19850307
AT	91233	E	19930715	AT 1985-102607	19850307
ZA	8501765	A	19851127	ZA 1985-1765	19850308
ES	541103	A1	19861016	ES 1985-541103	19850308
US	4757088	A	19880712	US 1986-939513	19861022
US	4914131	A	19900403	US 1989-338448	19890414
PRAI	US 1984-587398		19840308		
	WO 1985-US362		19850306		
	EP 1985-102607		19850307		
	US 1986-939513		19861022		
	US 1987-67230		19870629		

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:168754 CAPLUS
 DN 96:168754
 TI Multivitamin for treating **herpes** infections
 IN Girard, Michele; Baufle, Marie Chantal
 PA Fr.
 SO Fr. Demande, 8 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2484257	A1	19811218	FR 1980-13665	19800616
	FR 2484257	B3	19830311		
PRAI	FR 1980-13665		19800616		

=> d 120 5 6 all

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:45751 CAPLUS
 DN 104:45751
 TI Antiviral pharmaceutical preparations and their use
 IN Haines, Harold Gray; Dickens, Caroline Burgess
 PA Brigham, Dana, USA
 SO Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K031-16
 ICS A61K031-195
 ICI A61K031-195, A61K031-16
 CC 1-5 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 154344	A2	19850911	EP 1985-102607	19850307
	EP 154344	A3	19900613		
	EP 154344	B1	19930707		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4628063	A	19861209	US 1984-587398	19840308
	WO 8503862	A1	19850912	WO 1985-US362	19850306
	W: AU, BR, DK, FI, HU, JP, NO				
	AU 8540673	A1	19850924	AU 1985-40673	19850306
	AU 571072	B2	19880331		
	JP 61501325	T2	19860703	JP 1985-501264	19850306
	JP 06076317	B4	19940928		
	IL 74535	A1	19881230	IL 1985-74535	19850307
	AT 91233	E	19930715	AT 1985-102607	19850307
	ZA 8501765	A	19851127	ZA 1985-1765	19850308
	ES 541103	A1	19861016	ES 1985-541103	19850308
	US 4757088	A	19880712	US 1986-939513	19861022
	US 4914131	A	19900403	US 1989-338448	19890414
PRAI	US 1984-587398		19840308		
	WO 1985-US362		19850306		
	EP 1985-102607		19850307		
	US 1986-939513		19861022		
	US 1987-67230		19870629		

AB Lidocaine or lidocaine-HCl, in combination with panthenol or pantothenic acid, is effective in the treatment of **herpes** virus infections in humans. Thus, 14 human males suffering from recurring genital

herpes applied a lidocaine-HCl 40, dexpanthenol 50 mg/mL ointment to the affected areas 3 times a day. The pre-blister itching and pain assocd. with blisters were markedly reduced 15-20 min after the 1st application. All cases treated showed a definite abortion or shortening of the 7-10-day itching, blister, and scab cycle. All blisters cleared up after 2-3 days of application of the lidocaine-HCl ointment.

ST **herpes** treatment lidocaine dexpanthenol; virus **herpes** infection lidocaine dexpanthenol

IT Virus, animal

(**herpes**, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT Virus, animal

(**herpes** simplex, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT Virus, animal

(varicella-zoster, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT 73-78-9 **79-83-4** 81-13-0 137-58-6 16485-10-2

RL: BIOL (Biological study)

(**herpes** virus infection treatment with)

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 1982:168754 CAPLUS

DN 96:168754

TI Multivitamin for treating **herpes** infections

IN Girard, Michele; Baufle, Marie Chantal

PA Fr.

SO Fr. Demande, 8 pp.

CODEN: FRXXBL

DT Patent

LA French

IC A61K031-66; A61K031-07; A61K031-59; A61K031-195; A61K031-335; A61K031-395

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2484257	A1	19811218	FR 1980-13665	19800616
	FR 2484257	B3	19830311		
PRAI	FR 1980-13665		19800616		

AB All cases of **herpes** (recurrent, labial, genital) could be treated rapidly and efficiently by a multivitamin compn. contg. vitamin A [11103-57-4] trace, vitamin D3 [67-97-0] trace, vitamin B1 [59-43-8] 1-5, vitamin B2 [83-88-5] 1-5, vitamin B5 [**79-83-4**] 1-5, vitamin B6 [8059-24-3] 0.5-1, vitamin B8 [64060-35-1] 0.01-0.05, vitamin B9 [11096-55-2] 0.05-0.1, vitamin B12 [68-19-9] 0.001-0.002, vitamin C [50-81-7] 20-50, vitamin E [1406-18-4] 2-10, and vitamin PP [11032-50-1] 0.01-0.02 mg.

ST **herpes** treatment multivitamin; vitamin **herpes** infection

IT Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**herpes** infection treatment with, in humans)

IT Virus, animal

(**herpes**, infection with, multivitamin compn. for treatment of, in humans)

IT 50-81-7, biological studies 58-56-0 58-85-5 58-95-7 59-30-3, biological studies 59-43-8, biological studies 67-97-0 68-19-9

79-83-4 83-88-5, biological studies 98-92-0 **137-08-6**

146-17-8 1406-18-4 8059-24-3 11032-50-1 11096-55-2 11103-57-4

64060-35-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(herpes infection treatment with multivitamin compn. contg.,
in humans)

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8
L20 6 S L18 AND L5

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8
L20 6 S L18 AND L5

=> d 116 10-19

L16 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1997:606368 CAPLUS
DN 127:272289
TI Apoptotic DNA fragmentation, and its in vitro prevention by nicotinamide,
in lymphocytes from **HIV**-1-seropositive patients and in
HIV-1-infected MT-4 cells
AU Savarino, A.; Martini, C.; Orofino, G. C.; Cantamessa, C.; Castelli, L.;
Pich, P. G.; Sinicco, A.; Pugliese, A.
CS Department of Medical and Surgical Sciences, Section of Infectious
Diseases, University of Turin, Italy
SO Cell Biochemistry and Function (1997), 15(3), 171-179
CODEN: CBFUDH; ISSN: 0263-6484
PB Wiley
DT Journal
LA English

L16 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1997:79334 CAPLUS
DN 126:143042
TI Investigation of the potential role of membrane CD38 in protection against
cell death induced by **HIV**-1
AU Savarino, A.; Pugliese, A.; Martini, C.; Pich, P. G.; Pescarmona, G. P.;
Malavasi, F.
CS Department of Medical and Surgical Sciences, University of Torino, Turin,
Italy
SO Journal of Biological Regulators and Homeostatic Agents (1996), 10(1),
13-18
CODEN: JBRAER; ISSN: 0393-974X
PB Wichtig
DT Journal
LA English

L16 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1996:256739 CAPLUS
DN 124:299031
TI Growth control for cells encapsulated within bioartificial organs
IN Schinstine, Malcolm; Shoichet, Molly S.; Gentile, Frank T.; Hammang,
Joseph P.; Holland, Laura M.; Cain, Brian M.; Doherty, Edward J.; Winn,
Shelley R.; Aebischer, Patrick
PA Cytotherapeutics, Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9602646	A2	19960201	WO 1995-US9281	19950720
	WO 9602646	A3	19960517		
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5935849	A	19990810	US 1994-279773	19940720
	US 5843431	A	19981201	US 1995-432698	19950509
	AU 9531422	A1	19960216	AU 1995-31422	19950720
	AU 698624	B2	19981105		
	EP 771350	A1	19970507	EP 1995-927373	19950720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10506266	T2	19980623	JP 1995-505271	19950720
	BR 9508312	A	19990601	BR 1995-8312	19950720
	NO 9700156	A	19970320	NO 1997-156	19970114
	FI 9700217	A	19970117	FI 1997-217	19970117
PRAI	US 1994-279773	A	19940720		
	US 1995-432698	A	19950509		
	WO 1995-US9281	W	19950720		

L16 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1995:958459 CAPLUS

DN 124:7065

TI Biochemically active agents for chemical catalysis and cell receptor activation

IN Kossovsky, Nir; Sponsler, Edward; Gelman, Andrew; Rajguru, Samir

PA The Regents of the University of California, USA

SO U.S., 13 pp. Cont.-in-part of U.S. 5,334,394.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5460830	A	19951024	US 1993-145870	19931101
	US 5219577	A	19930615	US 1990-542255	19900622
	US 5178882	A	19930112	US 1991-690601	19910424
	JP 05255111	A2	19931005	JP 1991-178805	19910624
	JP 2932406	B2	19990809		
	US 5334394	A	19940802	US 1993-199	19930104
	US 5462750	A	19951031	US 1994-225100	19940408
	WO 9512392	A1	19950511	WO 1994-US12515	19941031
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2174244	AA	19950511	CA 1994-2174244	19941031
	EP 726767	A1	19960821	EP 1995-901094	19941031
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09504790	T2	19970513	JP 1994-513349	19941031
PRAI	US 1990-542255		19900622		
	US 1991-690601		19910424		
	US 1993-199		19930104		
	US 1993-986		19930106		
	US 1993-145870		19931101		
	US 1993-146536		19931101		
	US 1993-147751		19931104		
	WO 1994-US12515		19941031		

L16 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:673568 CAPLUS
 DN 123:109959
 TI **HIV** infection decreases intracellular nicotinamide adenine dinucleotide [NAD]
 AU Murray, Michael F.; Nghiem, Michael; Srinivasan, Alagarsamy
 CS Dep. Med., Univ. PA Sch. Med., Philadelphia, PA, USA
 SO Biochemical and Biophysical Research Communications (1995), 212(1), 126-31
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic
 DT Journal
 LA English

L16 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:590755 CAPLUS
 DN 123:357
 TI Nicotinamide inhibits **HIV**-1 in both acute and chronic in vitro infection
 AU Murray, Michael F.; Srinivasan, Alagarsamy
 CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
 SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic
 DT Journal
 LA English

L16 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:556533 CAPLUS
 DN 123:143841
 TI Synthesis and antiviral evaluation of fluorinated dipyrindodiazepinones and dipyrindodiazepines (nevirapine derivatives)
 AU Boyode, B. P.; Sinet, M.; Barese, A.; Forestier-Roux, M.-A.; Condom, R.; Ayl, I. A.; Kirn, A.; Moog, C.; Guedj, R.
 CS Faculte Sciences, Universite Nice-Sophia Antipolis, Nice, F-06108, Fr.
 SO Antiviral Chemistry & Chemotherapy (1995), 6(3), 162-8
 CODEN: ACCHEH; ISSN: 0956-3202
 PB Blackwell
 DT Journal
 LA English

L16 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:622844 CAPLUS
 DN 115:222844
 TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
 AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
 CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
 SO Voprosy Virusologii (1991), 36(3), 216-18
 CODEN: VVIRAT; ISSN: 0507-4088
 DT Journal
 LA Russian

L16 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald

CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

L16 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8904314	A1	19890518	WO 1988-NL48	19881102
	W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU				
	RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
	AU 8826199	A1	19890601	AU 1988-26199	19881102
	JP 02502096	T2	19900712	JP 1988-508750	19881102
	FI 8903279	A	19890705	FI 1989-3279	19890705
PRAI	IL 1987-84387		19871106		
	WO 1988-NL48		19881102		
OS	MARPAT 112:151841				

=> d 116 5-9

L16 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51504 CAPLUS
 DN 136:112623
 TI Zinc finger motif sequences from herpes simplex virus protein IE63 and
 uses thereof in drug screening for treating herpesvirus infection
 IN Clements, John Barklie; MacLean, Alasdair Roderick
 PA The University Court of the University of Glasgow, UK
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004492	A2	20020117	WO 2001-GB3114	20010711
	WO 2002004492	A3	20020510		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1299725	A2	20030409	EP 2001-949666	20010711

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI GB 2000-16890 A 20000711
WO 2001-GB3114 W 20010711

L16 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 2001:504998 CAPLUS

DN 136:273127

TI Increased plasma tryptophan in **HIV**-infected patients treated
with pharmacologic doses of nicotinamide

AU Murray, M. F.; Langan, M.; MacGregor, R. R.

CS Department of Medicine, Brigham and Women's Hospital, Harvard University,
Boston, MA, USA

SO Nutrition (New York, NY, United States) (2001), 17(7/8), 654-656
CODEN: NUTRER; ISSN: 0899-9007

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 2001:6065 CAPLUS

DN 134:37051

TI Method for immune-system strengthening and development of a lipid
transporter for anti-**HIV** and antibacterial gene therapy

IN Worm, Richard; Correa, Michel; Mavoungou, Donatien

PA Can.

SO Fr. Demande, 16 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2792201	A1	20001020	FR 1999-4706	19990415
	FR 2792201	B1	20011102		
PRAI	FR 1999-4706		19990415		

L16 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1999:454270 CAPLUS

DN 131:82943

TI Compositions and methods for identifying therapeutic agents and for
treating cells having double minute DNA

IN Wahl, Geoffrey M.; Shepard, H. Michael; Shimizu, Noriaki

PA Newbiotics, Inc., USA; The Salk Institute; Kanda, Teru

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9935292	A1	19990715	WO 1999-US601	19990111
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2318380	AA	19990715	CA 1999-2318380	19990111
AU 9922217	A1	19990726	AU 1999-22217	19990111
EP 1070140	A1	20010124	EP 1999-902175	19990111

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

BR 9906926	A	20020115	BR 1999-6926	19990111
JP 2002510033	T2	20020402	JP 2000-527673	19990111

PRAI US 1998-71146P P 19980112

US 1998-77644P P 19980311

WO 1999-US601 W 19990111

OS MARPAT 131:82943

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6350784	B1	20020226	US 1997-824041	19970326
	AU 9867718	A1	19981020	AU 1998-67718	19980324
	AU 727339	B2	20001207		
	BR 9807892	A	20000222	BR 1998-7892	19980324
	EP 980203	A1	20000223	EP 1998-913086	19980324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900436	A	20000417	EE 1999-436	19980324
	NZ 500002	A	20010928	NZ 1998-500002	19980324
	JP 2001527541	T2	20011225	JP 1998-545926	19980324
	NO 9904639	A	19991124	NO 1999-4639	19990924
	MX 9908750	A	20000331	MX 1999-8750	19990924
	BG 63612	B1	20020731	BG 1999-103786	19991007
PRAI	US 1997-824041	A	19970326		
	US 1996-600217	A2	19960212		
	US 1996-646988	A2	19960508		
	WO 1998-US5792	W	19980324		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 116 19 all

L16 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C07F009-10
 ICS C07F009-09; C07F009-58; A61K031-66
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 27

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8904314	A1	19890518	WO 1988-NL48	19881102
	W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU				
	RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
	AU 8826199	A1	19890601	AU 1988-26199	19881102
	JP 02502096	T2	19900712	JP 1988-508750	19881102
	FI 8903279	A	19890705	FI 1989-3279	19890705
PRAI	IL 1987-84387		19871106		
	WO 1988-NL48		19881102		
OS	MARPAT 112:151841				
AB	The acylglycerophosphate esters R1OCH2CH(OR2)CH2OP(O)(O-)GAzR3 [R1, R2 = H, fatty acyl; A = CH2, polymethylene, oxapolymethylene, thiapolymethylene, etc. R3 = (un)substituted Ph or pyridinium, etc.; G = O, S; Z = O, 1-18] are prepd. as virucides, suitable for treating human immunodeficiency virus (HIV) infections. 2-Hydroxyethyl-1-nicotinamide chloride (prepn. given) was transphosphatidylated enzymically, by the method of Eibel and Kovatchev (1981), to give phosphatidyl-2-hydroxyethyl-1-nicotinamide (I). I (20 .mu.g/mL) totally controlled HIV, in vitro, as shown by the method of Moore, et al. (1978).				
ST	virucide animal phospholipid; glycerophosphate deriv prepn AIDS drug				
IT	Phosphatidylethanolamines				
	RL: RCT (Reactant); RACT (Reactant or reagent) (acetylation of)				
IT	Phospholipids, biological studies				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (virucides, animal)				
IT	Immunodeficiency				
	(acquired immune deficiency syndrome, treatment of, with reaction products of acylglycerophosphates with alcs. and thiols)				
IT	Phosphatidic acids				
	RL: SPN (Synthetic preparation); PREP (Preparation) (esters, prepn. of, as animal virucides)				
IT	Virucides and Virustats				
	(medical, reaction products of acid glycerophosphates with alcs. or thiols)				
IT	Phosphatidylethanolamines				
	RL: SPN (Synthetic preparation); PREP (Preparation) (reaction products, with acetic anhydride, prepn. of, as animal virucide)				
IT	98-92-0, Nicotinamide				
	RL: BIOL (Biological study) (condensation of, with chloroethanol)				

IT 107-07-3, 2-Chloroethanol, biological studies
 RL: BIOL (Biological study)
 (condensation of, with nicotinamide)

IT 126235-31-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and transphosphatidylation of)

IT 58-27-5DP, reaction products with phosphatidylethanolamines 100-51-6DP,
 Benzenemethanol, reaction products with phosphatidic acids 108-24-7DP,
 reaction products with phosphatidylethanolamines 141-79-7DP, reaction
 products with phosphatidylethanolamines 126235-31-2DP, reaction products
 with phosphatidic acids
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as animal virucide)

IT 58-27-5, Menadione
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with phosphatidylethanolamine)

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
 L2 2 S VITAMIN B5
 L3 2 S VITAMIN B3
 L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
 E RETROVIRAL
 L6 13948 S E1-E6
 L7 50063 S HIV
 L8 61642 S L7 OR L6
 L9 8 S L5 AND L8
 L10 21260 S VITAMIN D
 L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
 L14 11658 S L3
 L15 4 S L13 AND L8
 L16 19 S L14 AND L8
 L17 15 S L16 NOT L15
 L18 27587 S HERPES OR HSV OR HHSV OR CMV
 L19 2073 S L18 AND L8
 L20 6 S L18 AND L5

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	83.56	212.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.21	-10.42

STN INTERNATIONAL LOGOFF AT 16:01:44 ON 07 JUL 2003

AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 CC 18-1 (Animal Nutrition)
 Section cross-reference(s): 14, 15
 AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally
 low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally
 high levels of some micronutrients were also found, but these were
 attributed to the ingestion of high supplement amts.
 ST micronutrient nutrition human immunodeficiency virus infection;
HIV infection diet micronutrient
 IT Carotenes and Carotenoids, biological studies
 Trace elements, biological studies
 Vitamins
 RL: BIOL (Biological study)
 (**HIV** virus infection in humans in relation to nutritional
 status of)
 IT Virus, animal
 (human immunodeficiency 1, humans infection by, micronutrient status in
 relation to)
 IT Nutrients
 (micro-, **HIV** virus infection in humans in relation to
 nutritional status of)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic
 acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6,
 Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12
79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological
 studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E
 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological
 studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium,
 biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A
 22150-76-1, Biopterin
 RL: BIOL (Biological study)
 (**HIV** virus infection in humans in relation to nutritional
 status of)

AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 CC 18-1 (Animal Nutrition)
 Section cross-reference(s): 14, 15
 AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally
 low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally
 high levels of some micronutrients were also found, but these were
 attributed to the ingestion of high supplement amts.
 ST micronutrient nutrition human immunodeficiency virus infection;
HIV infection diet micronutrient
 IT Carotenes and Carotenoids, biological studies
 Trace elements, biological studies
 Vitamins
 RL: BIOL (Biological study)
 (**HIV** virus infection in humans in relation to nutritional
 status of)
 IT Virus, animal
 (human immunodeficiency 1, humans infection by, micronutrient status in
 relation to)
 IT Nutrients
 (micro-, **HIV** virus infection in humans in relation to
 nutritional status of)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic
 acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6,
 Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12
 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological
 studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E
 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological
 studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium,
 biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A
 22150-76-1, Biopterin
 RL: BIOL (Biological study)
 (**HIV** virus infection in humans in relation to nutritional
 status of)

7

AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N033-12
 ICS A61K031-14
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842188	A1	19981001	WO 1998-US5792	19980324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6350784	B1	20020226	US 1997-824041	19970326
	AU 9867718	A1	19981020	AU 1998-67718	19980324
	AU 727339	B2	20001207		
	BR 9807892	A	20000222	BR 1998-7892	19980324
	EP 980203	A1	20000223	EP 1998-913086	19980324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900436	A	20000417	EE 1999-436	19980324
	NZ 500002	A	20010928	NZ 1998-500002	19980324
	JP 2001527541	T2	20011225	JP 1998-545926	19980324
	NO 9904639	A	19991124	NO 1999-4639	19990924
	MX 9908750	A	20000331	MX 1999-8750	19990924
	BG 63612	B1	20020731	BG 1999-103786	19991007
PRAI	US 1997-824041	A	19970326		
	US 1996-600217	A2	19960212		
	US 1996-646988	A2	19960508		
	WO 1998-US5792	W	19980324		
AB	An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.				
ST	phytochem nutrient antimicrobial HIV ; Echinacea Commiphora phytochem surfactant antimicrobial HIV ; folic acid phytochem antimicrobial HIV				
IT	Labia Lip Lymph node Lymphatic system T cell (lymphocyte) (administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)				

IT Quaternary ammonium compounds, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkylbenzyltrimethyl, bromides; antimicrobial prevention and treatment
 of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkylbenzyltrimethyl, chlorides; antimicrobial prevention and treatment
 of human immunodeficiency virus and other infectious diseases)

IT Surfactants
 (amphoteric; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Bacilli
 (anaerobic; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT Allium
 Anise
 Arctostaphylos
 Artemisia
 Baptisia
 Calendula
 Capsicum
 Carum
 Compositae (Asteraceae)
 Coriandrum
 Echinacea angustifolia
 Echinacea atribactilus
 Echinacea pallida
 Echinacea purpurea
 Echinacea vegetalis
 Eucalyptus
 Eugenia myrtacea
 Gentian (Gentiana)
 Inula
 Juniper (Juniperus)
 Labiatae (Lamiaceae)
 Meliosma
 Mentha
 Mentha aquatica
 Myroxylon
 Origanum
 Parthenium integrifolium
 Plantago
 Rosemary
 Ruta
 Sage (Salvia)
 (antimicrobial isolates of; antimicrobial prevention and treatment of
 human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
 Antibacterial agents
 Antimicrobial agents
 Antiviral agents
 Arbovirus
 Arenavirus
 Bird (Aves)
 Cat (Felis catus)
 Cattle
 Commiphora erythraea
 Commiphora molmol
 Commiphora myrrha
 Coronavirus
 Cytomegalovirus
 Dog (Canis familiaris)

Drug delivery systems
Gums and Mucilages
Horse (*Equus caballus*)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus
Livestock
Mycobacterium
Nutrients
Papillomavirus
Picornaviridae
Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis

(bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
Surfactants

(cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
(cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
(mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies

97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies
 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5,
 Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3,
 Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic
 acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8
 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9,
 Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5,
 .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3,
 Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid
 536-60-7, Cumic alcohol 548-75-4, Quercetagenin-7-glucoside 563-83-7
 593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone
 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6,
 Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E
 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide
 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies
 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic
 acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin
 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7,
 .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4,
 Magnesium, biological studies 7439-96-5, Manganese, biological studies
 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological
 studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium,
 biological studies 7723-14-0, Phosphorus, biological studies
 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronooarabinoxylan
 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
 biological studies 16887-00-6, Chloride, biological studies
 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
 Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0
 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
 69350-61-4, Epishyobunol 74282-22-7 75081-19-5, Pentadecadiene
 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
 125199-93-1 148879-89-4, Commiphoric acid 149531-55-5,
 .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
 .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7,
 Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium
 chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
 Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium
 chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(complex; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Bryant; US 4797420 A 1989 CAPLUS

(2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS

(3) Silverman; US 5455033 A 1995

(4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115

(5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994, P181

(6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

AN 1996:682599 CAPLUS
 DN 126:153113
 TI The effect of 1,25-vitamin D3 on maturation of monocytes from HIV
 -infected patients varies with degree of immunodeficiency
 AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S.
 S.
 CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027,
 Norway
 SO APMIS (1996), 104(7-8), 539-548
 CODEN: APMSEL; ISSN: 0903-4641
 PB Munksgaard
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 AB The active metabolite of vitamin D,
 1,25-dihydroxyvitamin D3 (1,25D), has been shown to induce
 monocyte-to-macrophage maturation in vitro as well as monocytic
 differentiation of bone marrow precursors and monocytic leukemic cell
 lines. In this study the authors assessed whether 1,25D could improve the
 maturation defect the authors have previously demonstrated in monocytes
 from AIDS patients. In vitro growth and maturation of monocytes from 10
 controls, 15 asymptomatic HIV pos. (CDC group II or III) and 13
 symptomatic HIV pos. (CDC group IV) was examd. by assessing
 cellular morphol., differentiation, adherence and protein content. Cells
 were cultured for 10 days with or without addn. of 1,25D at a concn. of
 100 pg/mL. In addn., patients were monitored clin. and by immunol.
 parameters and HIV p24 antigen in serum. The present study
 showed that addn. of 1,25D significantly improved the growth and
 maturation in both patient and control groups. There was a significant
 neg. correlation between response to 1,25D and CD4+ lymphocyte count in
 blood in HIV-infected patients. A greater response to 1,25D was
 seen in monocytes from patients with advanced immunodeficiency and
 symptomatic disease than in monocytes from asymptomatic patients.
 However, in the most advanced cases of HIV infection with
 serious ongoing opportunistic infections the response to 1,25D was very
 poor, possibly reflecting profound and incorrigible dysfunction of
 monocytes.
 ST dihydroxyvitamin D3 monocyte macrophage HIV1 AIDS
 IT AIDS (disease)
 Human immunodeficiency virus 1
 Immunodeficiency
 Macrophage
 Monocyte
 (effect of 1,25-vitamin D3 on maturation of monocytes from HIV
 -infected humans varies with degree of immunodeficiency)
 IT 32222-06-3, Ro 21-5535
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (effect of 1,25-vitamin D3 on maturation of monocytes from HIV
 -infected humans varies with degree of immunodeficiency)